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Zusammenfassung 
 
Das Pankreaskarzinom ist bei Frauen und Männern die 4. häufigste Krebstodesursache und 
besitzt  eine der schlechtesten Prognosen unter den malignen Erkrankungen. Gezeigt wurde, 
dass die ungesättigten Fettsäuren Arachidon- und Linolsäure Wachstum und Entstehung von 
Pankreaskarzinomen fördern. Zu den Arachidonsäure metabolisierenden Enzymen zählen 
die Cyclooxygenasen und Lipoxygenasen. Besonders letztere sind bei der Tumorgenese des 
Pankreas involviert. 
15-LOX-1 wird nur im normalen Gewebe aber nicht im Tumorgewebe oder in Tumorzellen 
exprimiert. Dies konnte sowohl auf mRNA also auch Proteinebene nachgewiesen werden. 
Auch in immunhistochemischen Färbungen konnte eine deutliche Abgrenzung der 15-LOX-1 
Expression zwischen normalem und erkranktem Gewebe nachgewiesen werden. Zusätzlich 
konnte die Expression der 15-LOX-1 in normalen, selbst isolierten und kultivierten 
Gangzellen nachgewiesen werden. Bei der Behandlung dieser normalen duktalen Zellen mit 
dem 15-LOX-1 Inhibitor, Kaffeesäure, konnte eine Zunahme der Proliferation um ca. 60% 
nachgewiesen werden. 
Eine Überexpression der 15-LOX-1 in zwei verschiedenen Tumorzelllinien führte zu einem 
verminderten Wachstum von bis zu 50%. Auch die exogene Behandlung mit dem Substrat 
Arachidonsäure und dem Produkt 15-HETE führte zu einem verminderten Wachstum. 
Anders verhielt es sich für das Substrat Linolsäure und das Produkt 13-HODE. Hier konnte 
kein Unterschied in der Proliferation beobachtet werden. Auf Zellzyklusebene konnte mittels 
FACS kein Unterschied zwischen 15-LOX-1 überexprimierenden und Mock Zellen 
beobachtet werden. Jedoch konnte in weiteren Versuchen eine gesteigerte Apoptoserate in 
den 15-LOX-1 exprimierenden Zellen nachgewiesen werden.  
Mit Hilfe des Histondeacetylaseinhibitors, Natriumbutyrat, konnte die Expression der           
15-LOX-1 in beiden getesteten Tumorzelllinien nachgewiesen werden. Zudem wurde eine 
drastische Abnahme in der Proliferation beobachtet. Zusätzlich konnte gezeigt werden, dass 
das anti-metastatische Protein KAI1 durch die Behandlung mit Natriumbutyrat wieder 
hergestellt werden konnte. Jedoch konnte kein Einfluss von Natriumbutyrat auf die 
Expression des pro-metastatischen Protein S100A4 beobachtet werden. 
Diese Ergebnisse lassen darauf schließen, dass 15-LOX-1 eine pro-apoptotische Wirkung 
hat und evtl. auch die Metastasierung durch den Verlust der 15-LOX-1 beeinflusst wird. 
Summary 
 
The results from epidemiological and animal studies suggest that a high  fat consumption  
is associated with an increased incidence and growth of tumors at several specific organ 
sites, including pancreas, colon, breast and prostate. Recently, the important role of 
lipoxygenase pathways in fat metabolism and in the regulation of pancreatic cancer  
cell proliferation and survival was identified. The arachidonic and linoleic acid metabolizing 
15-lipoxygenase-1 (15-LOX-1) acts anti-tumorigenic in colon, esophageal and gastric 
cancers. However, since nothing is known about 15-LOX-1 in pancreatic cancer, this was 
investigated in the present study. Expression of 15-LOX-1 was investigated by RT-PCR and 
western blotting in human pancreatic cancer cell lines and by immunohistochemistry in 
human pancreatic cancer tissues. Cell proliferation was analyzed in 15-LOX-1 
overexpressing pancreatic tumor cell lines and after treatment with both the substrates and 
products. Restored 15-LOX-1 expression after sodium butyrate treatment was analyzed by 
western blot analysis. RT-PCR and western blotting showed absence or very weak 
expression of 15-LOX-1 in all pancreatic cancer cell lines tested. 15-LOX-1 was strongly 
stained in normal ductal cells, tubular complexes and centroacinar cells, but no staining was 
seen in islets, cancer cells, PanIN lesions, or in tumor cells in lymph node metastases. 
Over-expression of 15-LOX-1 in pancreatic tumor cells or treatment with its downstream 
metabolite 15-S-HETE resulted in decreased cell growth whereas 13-S-HODE did not result 
in any altered proliferation. Treatment with the substrate AA reduced cell proliferation 
significantly though no effect was observed after LA treatment. 
On cell cycle progression level no difference between 15-LOX-1 expressing and mock cells 
was detectable. Though a clear increase in apoptosis was detected in 15-LOX-1 over-
expressing cells. 
A re-establishment of 15-LOX-1 in pancreatic tumor cell lines could be affirmed on protein 
level, further sodium butyrate incubation resulted in a strong regression of cell proliferation. 
Additionally, NaBu incubation restored expression of the anti-apoptotic protein KAI1 
whereas no effect on protein expression level was detectable for the pro-metastatic protein 
S100A4. 
This study shows that expression of the anti-tumorigenic 15-LOX-1 is suppressed in 
pancreatic cancer and already in PanINs. These findings provide evidence that loss of      
15-LOX-1 may play an important role in pancreatic carcinogenesis, possibly as a tumor 
suppressor gene. Lipoxygenases are attractive targets for the prevention and treatment of 
pancreatic cancer. Induction of 15-LOX-1 expression should be harmless for normal cells 
and, therefore, may be a valuable new anti-tumorigenic tool in the fight against pancreatic 
cancer. 
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1. The Pancreas 
 
1.1 Anatomy and Physiology  
 
The pancreas is an elongated, tapered organ located across the back of the abdomen and 
lying behind the stomach. It is made up of glandular tissue and a system of ducts. 
Anatomically, it is divided into head, body, and tail. The head is the broadest part of the 
gland. It is located in the right part of the abdomen nestled in the curve of the duodenum. 
The body links the part of the head and tail. The tail is the thin tip of the gland in the left part 
of the abdomen in close proximity with the spleen. The pancreas consists of two different 
tissue types: exocrine and endocrine [1]. 
1.1.1 Exocrine pancreas 
 
The exocrine tissue consists of acinar cells, which produce bicarbonate ions (HCO3-) and 
different digestive enzymes such as amylase and trypsinogen. These enzymes remain 
inactive until they reach the duodenum. They degrade carbohydrates, triglycerides, proteins, 
acids and vitamins in the duodenum [2]. Their secretion is regulated by several peptides 
released from the gastrointestinal tract. The exocrine tissue also secretes bicarbonate to 
neutralize gastric acid in the duodenum. 
The other part of the exocrine system consists of ductal cells. These cells secrete fluids and 
electrolytes. 
1.1.2 Endocrine pancreas 
 
The endocrine tissue consists of the islets of Langerhans which are divided into three main 
cell types: α-cells are responsible for the production of glucagon, an opponent of insulin that 
is produced by the β-cells. δ-cells secrete somatostatin which inhibits many digestive 
functions.  
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Fig 1: The Pancreas 
Picture taken from Books/ Cole Thomson Learning 
 
1.2 Pancreatic secretion 
1.2.1 Bicarbonate Secretion 
 
The pancreas secretes an isoosmotic juice at a daily rate of 1500-3000 ml. The pH of the 
juice ranges between 8.0 and 8.5. The juice contains enzymes for fat, carbohydrate, and 
protein digestion, water and electrolytes. The total concentration of the major anions Cl- and 
HCO3- approaches 150 mEq/l. The high pH of the juice after a meal neutralizes acidic gastric 
chyme and raises duodenal contents to an optimal pH for enzymatic digestion. Pancreatic 
juice also contains Ca2+ and traces of Mg2+, HPO42- and SO42-, although the role of theses 
electrolytes is not known [2].  
 
Introduction 
 
 - 3 – 
1.2.2 Enzyme Secretion 
 
Four classes of enzymes are secreted by the pancreas: 
• Proteolytic: trypsin and chymotrypsin belong to endopeptidases which are secreted 
as zymogens. Both are activated by enterokinases that are secreted by the mucosa 
of the proximal intestine. After activation trypsin activates further zymogens.  
• Lipolytic: The major component is the lipase which is secreted as an active enzyme. 
This enzyme hydrolyzes triglycerides to diglycerides, monoglycerides and fatty acids.  
• Carbohydrate-hydrolyzing: amylase is a member of this family. It hydrolyzes starch to 
maltose, maltotrioses and dextrins. 
• Nucleotic enzymes: these enzymes hydrolyze the phosphodiester bonds that link 
nucleotides in nucleic acid [2]. 
1.2.3 Regulation of Pancreatic Secretion 
 
There are two patterns of pancreatic secretion. The first pattern is basal secretion, which is 
punctuated every 1 to 2 hours by bursts of increased bicarbonate and enzyme secretion that 
last 10 to 15 minutes. The second pattern is the postprandial (after meal) stage, which 
results from complex interaction of neural and hormonal mechanisms [2]. 
Pancreatic secretion is regulated by several peptides that are released from the 
gastrointestinal tract, like secretin and cholecystokinin (CCK). These enzymes stimulate 
pancreatic secretion acting as a counterpart to somatostatin.  
All in all about 20 digestive enzymes and cofactors are secreted by the pancreas. These 
enzymes account for most of the intraluminal digestion of dietary proteins, triglycerides and 
carbohydrates. Even some vitamins (such as A and B12) are cleaved by these enzymes. 
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1.3 Pancreatic tumors 
 
The normal pancreas is composed of three major differentiated cell phenotypes. The cell 
lineages consist of acinar cells, ductal cells, and islet cells [3, 4]. Ductal markers include a 
secretory component [5, 6], carbonic anhydrase II, and cytokeratin 19 (CK19). Islet cell 
markers include chromogranin A, insulin, glucagon and somatostatin. Markers for acinar cells 
comprise trypsin, amylase and lipase. The majority of pancreatic tumors have morphologic 
characteristics of ductal epithelium, containing mucin and lacking secretory or zymogen 
granules [7, 8]. Pancreatic tumors can be divided into benign and malignant tumors occurring 
either from the endocrine or the exocrine part of the pancreas. Benign tumors are very rare 
and mostly originate from the endocrine system. Benign tumors occurring in the exocrine part 
of the pancreas include cystic neoplasias such as serous cystadenoma, mucinous 
cystadenoma and intraductal papillary mucinous neoplasia (IPMN). 
The most common type of malignant pancreatic tumors is the ductal adenocarcinoma (90%). 
Further exocrine malignant tumors like the squamous cell carcinoma, the acinar cell 
carcinoma and the cystadenocarcinoma are rare. Mucinous cystadenoma progress to 
mucinous cystadenocarcinoma and IPMNs develop from adenoma and borderline lesions 
finally to a malignant phenotype like an invasive ductal adenocarcinoma. Tumors also might 
appear in the connective tissue of the pancreas. They are called leiyomyoma or 
histiocytoma. Metastases of pancreatic cancer are most often found in local lymph nodes, 
liver, peritoneum, adrenal glands, lung, kidney, spleen and bone [9]. 
 
benign malignant
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system
endocrine
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Fig 2: Classification of pancreatic tumors 
 
Introduction 
 
 - 5 – 
1.3.1  Epidemiology and prognosis 
 
Epidemiology 
 
Pancreatic cancer is the tenth leading cancer disease in men and the ninth leading in 
women. Because of late diagnosis it is the fourth leading cause of cancer death in male and 
the fifth leading cause of cancer death in women [10] . During the last decade, the combined 
death rate of all cancers decreased by 1.5% per year among men and 0.8% per year among 
women. The mortality rate of pancreatic cancer, however, did not decrease compared to 
cancers of the lung, colon, prostate and breast. In the US,  32,300 people died  from 
pancreatic cancer and 33,730 new cases arose in 2006 [10]. Within the last three decades, 
the Five-year Survival Rate has only increased about 2% up to 5%. Since 1930, the ratio of 
incidence to mortality has not declined. In contrast, it has increased in Japanese and African 
mericans over the last decades [11-15]. In Europe, the highest mortality rates occur in 
Austria /year). The corresponding ratios in Southern 
(Spain, Portugal, and Greece) are generally lower. Mortality rates in Japan are now 
es in Western countries [16]. 
A
 and Sweden (around 11 per 100 000
Europe 
similar to rat
 
Survival 
abysmal cer 
pat
UROCARE 
cancer. 
there is need for identifying new targets for early prevention, diagnosis, and treatment 
tic cancer.  
 
 
Every year 10,000 people are diagnosed with pancreatic cancer in Germany. Males are more 
often affected than women. Today’s surgical methods and chemotherapies are not efficient 
for many patients [17]. The prognosis of pancreatic can is caused by the lack of 
therapeutic options and the late diagnosis. Only 9 - 20% of ients proceed to surgical 
resection and even then these patients have a poor long-term survival [18]. The median 
survival time is about 19 months when patients receive adjuvant chemotherapy [19]. 24 
months after surgery 95% of patients have recurrent disease [18]. 
From the E study, based on 31,312 European cases, survival at 1, 3 and 5 years 
was 16, 5, and 4%, respectively [20]. 
Five-year survival was better in patients with 15-44 years of age, with 15% compared to 6% 
or less for the 45 year old patients and above. Over time there were no changes in the 1, 3 
elative survival rates of pancreatic and 5-year r
Thus, 
of pancrea
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1.3.2  Development of pancreatic ductal adenocarcinoma (PDAC) 
 
Based on clinical and molecular studies, pancreatic ductal adenocarcinoma seems to follow 
a multi-step progression sequence from low-grade dysplasia to high-grade dysplasia and 
eventually to invasive carcinoma. However, it was difficult to compare studies investigating 
dysplasia in pancreatic ducts due to the lack of consensus regarding the terminology and 
criteria for grading. Some reports of precursor lesions suggested that these definitions do not 
Situ of the Pancreas" held in Japan in 2002. After this 
 on precursor lesions of pancreatic 
 of PanINs follows a progressive increase of cytological and 
rchitectural atypia from PanIN-1A to PanIN-1B characterized by increased crowding of cells 
ith early papillary projections, to PanIN-2 characterized by similar architectural appearance 
with Pa ch resemble 
arcinoma, at a cytological level, demonstrating severe atypia, necrosis, tufting and mitotic 
encompass the full spectrum of precursors of ductal carcinoma, and these issues were the 
subject of the "Forum on Carcinoma In 
forum, it became clear that the existing definitions of pancreatic intraepithelial neoplasias 
(PanINs) needed to be revised and expanded. Participants of the Pancreatic Cancer Think 
Tank and the Forum gathered together at a meeting
cancer in 2003, and an international consensus on the diagnostic criteria for PanINs was 
created [21]. Grading
a
w
nIN-1B but with mild to moderate nuclear atypia, and to PanIN-3 whi
c
activity. 
 
Fig 3: Process of PDAC development 
Many stimuli like the oncogene K-ras or cytokines that are involved in inflammation lead to increased cell proliferation and DNA 
damage. Some checkpoints during cell cycle or senescence are necessary to control normal cell fate and activate apoptosis 
when necessary. If cell cycle controlling proteins like the tumor suppressor gene products p16 or p53 are abrogated as indicated 
in this figure, cells are not able to undergo apoptosis which may prevent genetically damaged cells to be removed. Instead, 
changes accumulate and cause the different grades of PanINs when PDAC is developing [22] ( slightly modified by 
uthor).  
genomic 
a
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Molecular evidence also supports that this progression is characterized by gradual 
accumulation of genetic alterations in cancer-associated genes. It leads to inactivation of 
tumor suppressor genes as well as over-expression or aberrant activation of oncoproteins. 
These alterations can be categorized as ‘early’ such as K-ras mutation, HER-2/neu, prostate 
stem cell antigen, MUC5 and fascin over-expression; ‘intermediate’ such as p16 inactivation, 
MUC1 and cyclin D1 over-expression; and finally as ‘late’ such as p53 deletion, BRCA2 
mutation, and over-expression of Ki-67, 14-3-3σ and mesothelin [23]. There are other 
proteins e.g. 5-lipoxygenase (5-LOX), E-cadherin, β-catenin (cadherin), which are supposed 
to play a role in the development of PanINs and thereby PDAC [22, 24]. Gene expression 
studies also revealed a frequent up-regulation of extrapancreatic foregut markers in early 
PanIN lesions (pepsinogen C, MUC6, KLF4, and TFF19 Sox-2, gastrin, HoxA5, GATA4/5/6, 
 and suggest that PanIN development may involve Hedgehog-villin and forkhead 6 (Foxll))
mediated conversion to a gastric epithelial differentiation program. 
1.3.3 Molecular genetics of PDAC 
 
The molecular analysis of evolving PDAC has provided an outline of genetic lesions, often 
implicating known cancer genes and classical cancer signalling cascades. In the following, 
several genes involved in the development of pancreatic cancer will be described: 
The K-ras oncogene and its signaling pathways 
K-ras is a member of the Ras family of GTP-binding proteins that mediate a wide variety of 
cellular functions including proliferation, differentiation, and survival [25, 26]. Although, K-Ras 
is a GTPase, its intrinsic activity is inefficient and requires GTPase activating proteins 
(GAPs) to promote GTP hydrolysis and attenuate downstream signaling. Activating K-ras 
point mutations in codon 12 (GGT to GAT) result in substitution of glycine with aspartate, 
thereby preventing the intrinsic and GAP-catalyzed hydrolysis of GTP. These mutations are 
the first known genetic alterations, occurring sporadically in normal pancreas. They are 
detected in ~30% of early neoplasms with the frequency rising to nearly 100% in advanced 
PDAC multiple effector pathways, mainly the Raf-
mitogen-activated protein kinase (MAPK) and phophoinositide-3-kinase (PI3K) pathways.  
[27, 28]. Activated K-Ras engages 
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The Raf-MAPK pathway 
The Raf family of serine-threonine kinases, which are bound by activated Ras, lead to 
MAPK/ERK kinase activation through a series of phosphorylation events resulting in 
proliferation [29]. The importance of Raf in cancer was obvious after the identification of 
activating B-Raf mutations in many malignancies, including melanoma, papillary thyroid, 
colorectal, and serous ovarian cancers. B-Raf mutations are rare in PDAC but ~33% of the 
histologically distinct pancreatic medullary carcinomas, a recently described rare variant of 
pancreatic adenocarcinoma, carry this mutation [30]. An analysis of nine pancreatic cancer 
tissues revealed JNK activation in all tumor samples [31]. Inhibition of MAPK results in 
decreased proliferation of PDAC cell lines and cell cycle arrest. 
Phosphoinositide 3-kinase (PI3K) 
The PI3K signaling pathway, which can be activated by Ras [32], regulates cell survival, size, 
nd proliferation via several downstream effectors including Akt, p70-S5K and the small 
GTPase RAC [33, 34]. Mutations in the PI3K pathway that are common in other cancer 
g mutations of the catalytic subunit of PI3K and loss-of-function 
of 
P PDAC, pos
T
a
types, including activatin
mutants the PTEN tumor suppressor, have not been commonly observed in PDAC        
[35, 36]. However, there are reports of decreased TEN expression in sibly due 
to promoter hypermethylation [37]. he downstream effector Akt2 is amplified in 10%-20% of 
PDAC, providing genetic evidence for a role of this pathway in this tumor type [38-41]. 
Additionally, inhibitors of PI3K appear to increase the sensitivity of PDAC cell lines to 
chemotherapy as well as TNF-α-induced apoptosis and diminish serum-induced cell 
proliferation [42-44]. 
Nuclear factor κB (NFκB) 
The NFκB transcription factor may be another important downstream mediator of mutated K-
tion of this pathway occurs in response to a variety of cell 
d 
ancreas how 
ras signaling in PDAC [45]. Activa
stress through stimulation by pro-inflammatory cytokines and growth factors, and is known to 
regulate the immune response, apoptosis, and many other processes [46-48]. Constitutive 
activation is observed in many cancers, where it is thought to contribute to cell survival, 
angiogenesis, and invasion [49]. Most primary pancreatic cancers an cell lines, but not 
normal p specimens, s constitutive NFκB activation [50, 51]. The NFκB pathway 
may also contribute to the prominent chemoresistance of PDAC [52] perhaps via its capacity 
to up-regulate Bcl-2 and Bcl-xl, as well as many other anti-apoptotic proteins. 
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p53 tumor suppressor gene 
The p53 tumor suppressor gene is mutated, generally by missense alterations of the DNA-
binding domain, in >50% of PDAC cases [28]. Consistent with an advanced malignant 
 appears in later-stage PanINs that have acquired significant 
features of dysplasia [53, 54]. Loss of p53 function could serve to enable the growth and 
progression, p53 mutation
survival of cells harboring pro-carcinogenic chromosomal aberrations [55]. 
p16INK4A-Rb 
P16 -Rb is a tumor suppressor system, which is critically involved in the molecular 
regulation of oncogene-induced premature senescence. The INK4A protein inhibits cell-cycle 
progression as an inhibitor of the cyclin D/ cyclin-dependent kinase 4/6 complex, indirectly 
influencing the activation status of the Rb protein. Inactivation of INK4A occurs in up to 95% 
of ductal pancreatic cancers, thus suggesting that the overcoming of the P16
INK4A
INK4A-Rb security 
program is absolutely necessary in PDAC [28, 56-58]. 
TGF-β 
ous epithelial cell 
lines and in epithelial tissue in vivo, TGF-β exerts a growth inhibitory program that involves 
f cell cycle regulators, including induction of p15INK4B and p21CIP1 expression and 
repression of c-myc, as well as induction of the apoptotic machinery [59]. Likewise, 
relative to normal pancreas and may 
promote the characteristic desmoplastic response of this malignancy as suggested 
from xenograft studies [65]. TGF-β signaling may also contribute to tumorigenesis in an 
TGF-β is the prototypic member of a super-family of secreted proteins. These growth factors 
signal through serine/threonine kinase receptor complexes. Upon ligand binding they, 
phosphorylate receptor-regulated Smad proteins that regulate a variety of cellular functions 
including proliferation, differentiation, migration, and apoptosis. In numer
modulation o
elevations in TGF-β signaling inhibit epithelial cancer initiation in vivo, and lesions in this 
pathway promote intestinal, ovarian, and pancreatic tumorigenesis. On the other hand, TGF-
β promotes proliferation and transformation of fibroblasts and the epithelial-to-mesenchymal 
transition in breast and skin cancer by which advanced carcinomas lose their differentiated 
features and acquire a highly aggressive, invasive phenotype [60-63]. TGF-β family ligands 
are expressed at elevated levels in PDAC cells [64] 
help to 
autocrine manner since PDAC often over-express the type II TGF-β receptor relative to 
normal pancreas [66]. Furthermore, antibodies to TGF-β inhibit the invasion of PDAC cell 
lines in vitro [67]. 
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The BRCA2 tumor suppressor 
Inherited BRCA2 mutations are typically associated with familial breast and ovarian cancer 
syndrome, but also carry a significant risk for the development of pancreatic cancer. One 
study estimated that ~17% of pancreatic cancers occurring in a familial setting harbor 
mutations in this gene [68]. BRCA2 is known to play a critical role in the maintenance of 
genomic stability by regulating homologous recombination-based DNA repair processes [69]. 
The fact that BRCA2 is selectively mutated late in tumorigenesis likely reflects the need for 
DNA damage response pathways to be inactivated first, so that the genetic damage incurred 
can be tolerated.  
1.3.4. Apoptosis resistance in pancreatic cancer cell lines 
 
The apoptosis-sensing, -inducing, and executing machinery is regulated at multiple levels, 
whereby every level can be disturbed in cancer cells, leading to an apoptosis-resistant 
ancer cells, the executive machinery is intact, and resistance 
mechanisms have evolved that work especially at the death-receptor level, mitochondrial 
se receptors, the death-inducing signaling complex (DISC) is formed, and 
the api leads to cleavage of 
the executioner caspases (caspase 3, caspase 6, and caspase 7) whose activity is 
sponsible for the typical morphological and biochemical changes of apoptosis [76]. C-FlipL 
phenotype [70]. In pancreatic c
level, and caspase-inhibitor level [71, 72]. Activation of apoptosis is triggered by two 
pathways [73]: the extrinsic and the intrinsic pathway. The extrinsic pathway is activated by 
the binding of the so-called death receptors, such as FAS/CD95, tumor necrosis factor (TNF) 
receptor, or TRAIL receptor, through their ligands, FAS-L, CD95L, TNF-α, or tumor necrosis 
factor-related apoptosis-inducing ligand (TRAIL). Most pancreatic cancer cells are resistant 
toward CD95L, TRAIL, or TNF-α-mediated apoptosis, although they express the 
corresponding death receptors [74, 75]. 
Upon binding to the
cal inducer caspase, caspase 8, is activated. Active caspase 8 
re
(caspase 8 homologue) is a potent inhibitor of caspase 8 activation and determines death-
receptor induced sensitivity [77]. C-FlipL is overexpressed in pancreatic cancer and is 
consequently one limiting factor for the therapeutic application of death receptor-based 
therapies [78, 79]. 
The central player of the intrinsic pathway is the mitochondrium, which triggers apoptosis 
upon lack of survival factors, stress or cellular injury. The alteration of the cellular situation 
are sensed by the proapoptotic BH3-only Bcl-2 family members, such as Bim, Bid, Bad, Bmf, 
Blk, Hrk, Noxa, or Puma. Once activated, BH3-only proteins act to antagonize the prosurvival 
functions of Bcl-2 or its homologues Bclxl or Mcl-1. This leads to permeabilization of the 
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mitochondrial membrane by ax-like proteins [80]. The permeabilization the 
release of death factors, such as cyctoc
B promotes 
hrome c, from the intramembraneous mitochondrial 
ioner caspase activity [85]. At least for the family members Xiap and 
.  
space [81]. 
At the mitochondrial level, a deregulated expression of members of the Bcl-2 family was 
shown in PDAC. In contrast to Bcl-2, whose expression is not significantly altered, Bclxl is 
overexpressed, thus suggesting an important role for this pro-survival Bcl-2 family member in 
apoptosis resistance [82-84]. 
The third level of apoptosis resistance is conferred by the inhibitor of apoptosis protein (IAP) 
family, including cIAP1, cIAP2, Xiap, and Survivin. One molecular action of this protein family 
is to inhibit execut
Survivin, increased protein expression could be shown [79, 86, 87]. It is interesting to note 
that nearly all molecules that mediate apoptosis resistance in pancreatic cancer cells are 
controlled by the transcription factor family NF-κB (already introduced). Recently, NF-κB has 
been shown to be constitutively activated in PDAC [51, 88]. In summary, pancreatic cancer 
cells have evolved multiple anti-apoptotic strategies which are possible targets for effective 
novel chemotherapeutics. Recently, numerous apoptosis-inducing agents, e.g. histone 
deacetylase inhibitors have been shown to have potent activities against various types of 
cancer cells
1.3.5 Metastasis 
 
After the initial neoplastic transformation, the tumor cells undergo progressive proliferation 
reate 
or cells have reached the vascular or lymphatic compartment, they must 
survive a variety of hemodynamic and immunologic challenges. However, some tumor cells 
evade illance by a variety of mechanisms such as down-regulation of  
HC I [91] and secretion of Fas ligand [92]. After survival in the circulation, tumor cells must 
arrest in distant organs or lymph nodes.  Arrested tumor cells extravasate before 
that is accompanied by further genetic changes and development of a heterogeneous tumor 
cell population with varying degrees of metastatic potential [89]. The initial growth of the 
primary tumor is supported by the surrounding tissue microenvironment, which eventually 
becomes rate-limiting for further growth. As the tumor grows and the central tumor cells 
become hypoxic, the tumor initiates recruitment of its own blood supply (angiogenesis). 
Invasive tumor cells down-regulate cell-cell adhesion by modulating the expression of 
cadherins, alter their attachment to the extracellular matrix by changing integrin expression 
profile and proteolytically alter the matrix by secretion of matrix metalloproteinases [90]. 
These changes result in increased cell motility. Invasive cells can detach from the primary 
tumor and c defects in the extra-cellular matrix, thus accomplishing stromal invasion. 
Once the tum
the immune surve
M
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proliferating. After extravasation, tumor cells migrate to a local environment more favorable 
for their continued growth. The process of tumor metastasis requires a coordination of the 
actions of many positive and negative factors. The fact that fusing a non-metastatic cell with 
a highly metastatic cancer cell results in suppression of metastatic ability of the tumor cell 
leads to the hypothesis that tumor metastasis is negatively regulated by tumor metastasis 
suppressor genes [93]. One of these genes is KAI1. The KAI1 gene was isolated originally as 
 
a prostate-specific tumor metastasis suppressor gene [94]. It is located in the p11.2 region of 
chromosome 11 [95]. KAI1 is a typical type III integral membrane protein that belongs to a 
structurally distinct family of membrane glycoproteins (tetraspanins) [96]. These proteins are 
characterized by the presence of 4 highly conserved hydrophobic domains, which are 
presumed to span the cell membrane, and one large extracellular N-glycosylated domain. 
They function via cell-cell and cell-extracellular matrix interactions, thereby potentially 
influencing the ability of cancer cells to invade tissue and to metastasize [94]. KAI1 
associates with other tetraspanins such as CD9, CD63, and CD81 in the plasma membrane 
and forms transmembrane complexes [97]. KAI1 is down-regulated during tumor progression 
in prostate [94], lung [98], breast [99], bladder [100], and pancreatic cancers [96, 101].
Another protein that is not less important than Kai1 for metastasis is S100A4, also called 
mts1, p9Ka, calvasculin, CAPL, pEL98. It is a member of a family containing 16 S100 
calcium-binding proteins, that all have in common a functional EF-hand domain that 
mediates their activity [102, 103]. S100A4 is thought to promote metastasis. In fact, non-
metastatic tumor cell lines that were transfected with S100A4 have a higher incidence of 
metastasis and show increased motility [104]. Rosty et al confirmed the over-expression of 
S100A4  in pancreatic carcinoma cell lines. Expression of S100A4 is associated with poor 
differentiation of the PDAC. Hypomethylation of CpG sites in the promoter has been found to 
be associated with the over-expression of S100A4 in colorectal cancer, lymphoma and 
PDAC cell lines. It is suggested that the majority of pancreatic carcinomas undergo selection 
for hypomethylation and overexpression of S100A4. 
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1.3.6 Risk factors  
 
• Familial pancreatic cancer 
It has been estimated that between 5 and 10% of pancreatic cancer cases are due to 
hereditary factors. Four case-control studies and 1 cohort study reported 3 to 5-fold higher 
risk among individuals with close relationship to a diseased person. No single pancreatic 
ancer gene has been reported to date, but a number of inherited cancer syndromes have 
een associated with increased PDAC cases. Among them are familial breast cancer 
RCA2 mutation), familial atypical multiple mole melanoma syndrome (FAMMM), hereditary 
ancreatitis, hereditary non-polyposis colorectal carcinoma (HNPCC), and Peutz-Jeghers 
yndrome [105]. 
• Tobacco 
levated mortality rates of pancreatic cancer among smokers have been reported 
onsistently. Relative risk for pancreatic cancer have generally ranged between 1.5 and 3 for 
urrent smokers versus non-smokers, and dose-response relationships between increasing 
ose or duration of cigarette smoking and pancreatic cancer have been observed in a 
numbe . Carcinogens from cigarette smoke such as aromatic and 
heterocyclic amines may be responsible for this activity. 
ancreatitis 
Ind u chronic pancreatitis have an increased risk of pancreatic cancer as 
 d
ts [111, 112]. On the other hand, 
acute p ear to be related to an increased risk of pancreatic cancer. 
c
b
(B
p
s
E
c
c
d
r of studies [105]
• Aspirin and NSAID use  
Data from experimental studies suggest that non-steroidal anti-inflammatory drugs (NSAIDs) 
inhibit pancreatic cancer [105]. Two case-control studies reported no association between 
aspirin or NSAID use or duration of use and the risk of pancreatic cancer [106, 107]. In a 
large case-control study, a statistically significant 49% increase in risk was observed among 
patients with 7 or more prescriptions as compared to patients with none [108]. Thus, whether 
or not aspirin use is rather protective against or is a risk factor for pancreatic cancer remains 
controversial. 
• Chronic p
ivid als with 
compared to healthy populations. In a multinational cohort study a standar ized incidence 
ratio (SIR=16.5) was observed. SIR is the ratio of the observed to the expected new cases of 
cancer. Two other studies have also reported a high risk of pancreatic cancer in patients with 
chronic pancreatitis when compared to the general population SIR=19 [109] and SIR=18.5 
[110]. Others have argued that chronic pancreatitis is not likely to be causally related to 
pancreatic cancer based on their observations in 2 cohor
ancreatitis does not app
Therefore, it is likely that the prolonged inflammation observed in chronic pancreatitis is 
responsible for the initiation or progression of pancreatic cancer. 
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• Cholecystectomy and cholelithiasis 
A number of case-control studies reported elevated pancreatic cancer risk among individuals 
with a history of gallbladder disease (cholelithiasis) [113-115] or among individuals who had 
their gallbladder removed (cholecystectomy) [113, 116]. However, other studies could not 
confirm these results [117-119]. Considering the existing data, it is not clear whether or not 
cho y hiasis have an impact on pancreatic carcinogenesis. 
d [120]. 71% of the glucose 
into a ents is unknown before the cancer is diagnosed 
ta suggest 
tha a e causally related to the insulin resistance and diabetes seen in 
lec stectomy and cholelit
• Diabetes mellitus  
Late-onset diabetes (type II) has been consistently associated with an elevated risk of 
pancreatic cancer [105]. However, the causal relationship has been questioned, given that 
diabetes also could be a consequence of pancreatic cancer. Enhanced risk may be due to 
elevated glucose concentration, hyperinsulinemia and gradual impaired glucose tolerance. In 
a case-control study, diabetics for more than 5 years before diagnosis had a 2-fold increased 
risk of pancreatic cancer, though those receiving insulin had a 6-fold increase in risk 
compared to those getting oral antidiabetics. 
The majority of diabetes associated with pancreatic cancer is diagnosed either concomitantly 
with the cancer or during the two years before the cancer is foun
ler nce found in pancreatic cancer pati
[121]. Therefore, recently-developed glucose intolerance or diabetes may be a consequence 
of pancreatic cancer and important as an early sign of the disease. Several studies have 
demonstrated that diabetes in pancreatic cancer patients is characterized by peripheral 
insulin resistance [120-122]. Insulin resistance is also found in non-diabetic or glucose 
intolerant pancreatic cancer patients, though to a lesser degree [122]. These da
t p ncreatic tumors ar
pancreatic cancer patients. Basso et al  found a 2030 MW peptide (S100A8 N-terminal 
peptide) in sera from pancreatic cancer patients that they considered to be a putative 
pancreatic cancer associated diabetogenic factor [123]. This peptide impairs the catabolism 
of glucose by myoblasts in vitro and may cause hyperglycemia in vivo assuming that its 
identification in biological fluids might be helpful in diagnosing pancreatic cancer in patients 
with recent onset diabetes mellitus [124]. 
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• Dietary factors 
The pancreas is intimately related to digestion and absorption of nutrients, hence it is 
consequential to place diet among th possible causal factors for PDAC. However, the 
pancreas is never exposed to ingested or absorbed foods, directly or indirectly. Therefore, 
the effects of diet on carcinogenesis in the pancreas must be via changes in the internal 
metabolic environment of that organ, exposure to blood-circulation, or even both. 
The results from epidemiological and animal studies suggest that a high fat consumption is 
associated with an increased incidence a
 e 
nd growth of tumors at several specific organ sites 
cluding pancreas, colon, breast and prostate [17]. In these tissues, it has been 
emonstrated that linoleic acid promotes carcinogenesis. 
 Out of 13 cohort studies, only 3 reported an elevated cancer risk for higher coffee 
take [125-127]. Based on the existing literature in 1991, the International Agency for 
esearch on Cancer (IARC) concluded, that there was little evidence to support a causal 
lation between coffee and risk of pancreatic cancer [128]. 
Alc o ive studies have examined the influence of alcohol intake in non-
umption of 
ulation of pancreatic cancer cell 
roliferation and survival. 
 
 
in
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alcoholic populations [125-127, 129-135]. Overall, and taking into account additional data 
from other case-control studies, it appears unlikely that alcohol plays a major role in 
pancreatic cancer. 
 
Fatty acids: Some studies suggest that high sugar intake together with high cons
fatty acids (FAs) like saturated FAs  (p=0.01), such as palmitic acid (p=0.02), stearic acid    
(p=0.04) and monounsaturated FAs (p=0.02), such as oleic acid (p=0.04) increase the risk of 
pancreatic cancer [136]. Recent reviews pointed out the important role of lipoxygenase 
pathways (see 2.0.) in fat metabolism and in the reg
p
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2. Fatty acids and lipoxygenases 
 
Although the role of individual fatty acids in human risk has been poorly investigated 
up to now, some recent epidemiological and xperimental data have
cancer 
 e hig
id
of ω-3 PUFAs such as docosahexaenoic acid (C22:6), to 
increased risks for cancers of the breast, colon and, possibly, prostate [137-139]. ω-6 PUFAs 
enhance tumorigenesis and metastasis in experimental animals by several mechanisms, 
whereas ω-3 PUFAs can inhibit the growth of initiated cancer cells [140]. Furthermore, 
persistent oxidative stress, often involving enhanced peroxidation of PUFAs in cell 
membranes by intracellularly produced O- and N-centered free radicals and altered cellular 
redox p ial are now known to enhance the development of malignant diseases. Thus, the 
carcinogenic process could be initiated and/or accelerated by lipid peroxidation-induced DNA 
and protein damage. The presence of exocyclic DNA adducts together with oxidized DNA 
base damage has been reported in human tissues and cells [140]. 
 
 linked a h dietary 
intake of ω-6 polyunsaturated fatty acids (PUFAs) such as linoleic ac  (C18:2), especially in 
association with a low intake 
otent
2.1 Fatty acids 
A typical fatty acid consists of an unbranched hydrocarbon chain with a carboxyl group at 
one end. Most naturally occurring fatty acids have an even number of carbons, with chain 
length of 16 and 18 being the most common. 
2.1.1 Saturated fatty acids 
 
Saturated fatty acids do not contain any double bonds or other functional groups along the 
chain. Of the fatty acids listed, acetic acid does not occur in natural fats oils, but vinegar 
contains approximately 5% acetic acid. Butyric acid is also uncommon in natural fats other 
than milk fat. Myristic acid is a major fatty acid in nutmeg, coconut, and palm kernal oil; 
palmitic acid and stearic acid are the most abundant saturated fatty acids in animal and 
human fat, accounting for 30% to 40% of the fatty acids in adipose tissue [141]. 
and 
2.1.2 Monounsaturated fatty acids 
 
Monounsaturated fatty acids have one carbon-carbon double bound. There is no free rotation 
around the double bond, and the substituents are fixed in cis or trans configuration. The most 
common fatty acid in animals is oleic acid. 
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2.1.3 Polyunsaturated fatty acids 
6 fatty acids have a double bond six carbons 
away from the terminal methyl carbon [141].  
mega-3 fatty acids
Polyunsaturated fatty acids (PUFAs) carry more than one double bound. Two types of 
PUFAs are distinguished. Omega-3 fatty acids have a double bond three carbons away from 
the terminal methyl carbon, whereas omega-
O  
d in linseed, 
rapeseed, walnut and blackcurrant oils. Deep cold-water fatty fish are rich sources of ω-3 
fatty ac od chain is based on ω-3 fatty acids, which are 
resent in the plankton and algae [140]. 
Important omega-3 fatty acids in nutrition are: α-linolenic acid (ALA), eicosapentaenoic acid 
(EPA), and docosahexaenoic acid (DHA). The human body cannot synthesize omega-3 fatty 
acids de novo, but can convert the omega-3 fatty acid ALA to other omega-3 fatty acids 
through chain elongation and desaturation. Therefore, ALA is an essential nutrient which 
must be obtained from food. ALA (ω-3) is found in dark green leafy plants an
ids (EPA and DHA) and the marine fo
p
Omega-6 fatty acids 
 
Important omega-6 fatty acids in nutrition are: Linoleic acid, Gamma-linolenic acid, 
Eicosa ic acid, Arachidonic acid, Docosadienoic acid 
Adrenic acid, Docosapentaenoic acid, and Calendic acid. Linoleic acid, the essential ω-6 fatty 
ancer 
dienoic acid, Dihomo-gamma-linolen
acid is found in vegetable seeds and oils such as those from safflower, sunflowers, soybeans 
and corn. 
2.1.4 Polyunsaturated fatty acids and c   
tion of various fatty acids to dietary intake differs widely among 
countries, as do the incidences of many cancers. In Italy and Spain, for example, where olive 
 
meta-analysis of data on mammary tumor incidence 
The relative contribu
oil is the predominant edible oil, the incidence of breast cancer is lower than that in North 
America and Northern Europe [142], and Greek women, who consume 42% of their energy 
supply as fat, mainly from olive oil have significantly lower rates of breast cancer than women 
in the USA, whose energy intake from fat is ~35% from different origin. Eskimos, who eat fish 
and meat from marine mammals rich in ω-3 fatty acids, and Japanese fishermen, who have 
the highest consumption of fish per head in the world, have high blood levels of long chain ω-
3 PUFAs such as EPA and low rates of cancers of the breast and colon, despite their overall 
high fat consumption. Fay  conducted a 
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extracted from 97 reports of experiments involving over 12,800 mice and rats to study the 
ffects of saturated and monounsaturated fats and ω-6 PUFAs and ω-3 PUFAs [143]. The 
saturated fat when they represented >4% of the caloric intake. Karmali  first 
reported a difference in the effects of ω-3 and ω-6 PUFAs on the growth of transplantable 
mamm ivity of ω-6 PUFAs was abrogated by 
e
results indicated that ω-6 PUFAs have a strong and saturated fats a weaker tumor-enhancing 
effect, whereas the ω-3 PUFAs have a small, statistically non-significant protective effect; 
while monounsaturated fats had no significant effect. ω-6 PUFAs had a stronger tumor-
enhancing effect when they represented <4% of total calories, but the effect was still stronger 
than that of 
ary tumors, in which the tumor-promoting act
competitive inhibition by ω-3 PUFAs [144, 145]. Several studies subsequently showed that 
diets containing corn oil, with high levels of ω-6 PUFAs such as linoleic acid, enhance breast 
and colon tumorigenesis in rodents, whereas fish oil, which is rich in the ω-3 PUFAs 
eicosapentaenoic acid and docosahexaenoic acid, reduces carcinogenesis [146]. There is 
now also evidence that consumption of ω-3 PUFAs is associated with reduced mortality from 
cardiovascular disease [147]. 
Mechanisms in fat-related carcinogenesis 
 
The existence of a causal relationship between a high dietary fat intake and increased cancer 
risk has been controversial for a long time, partly because of the lack of consensus on the 
mechanisms of action of dietary fat in mammalian cells. Dietary fats, specifically ω-6 and ω-3 
PUFAs, affect a variety of steps in the multistage carcinogenesis process, adding further
weight to a causal relationship. The effects may be direct or indirect and include: (i) 
peroxidation of conjugated double bonds in PUFAs, leading to persistent oxidative stress and 
generation of reactive lipid peroxidation products (malondialdehyde, 4-hydroxyalkenals),
which can induce DNA damage; (ii) conversion of essential fatty acids to eicosanoids by 
cyclooxygenases and lipoxygenases, short-lived hormone-like lipids derived primarily from 
dietary arachidonic acid; (iii) interaction of fatty acids with signal transduction pathways 
leading to altered gene expression; (iv) effects on membrane (lipid)-bound enzymes such as 
cytochrome P450 (CYP), (v) structural and functional changes in cell membranes resulting in 
alterations of hormone and growth factor receptors [140]. 
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Effects on cell proliferation and signal transduction 
 
Fatty acids may regulate cellular functions by affecting the expression or activity of genes in 
the signal transduction pathway related to the control of cell growth and apoptosis. High 
intake of ω-6 PUFAs induces various physiological and metabolic effects [146, 148] (i) 
increased ornithine decarboxylase activity in colonic mucosa, resulting in enhanced epithelial 
polyamine levels and increased colonic crypt cell proliferation; (ii) enhanced activities of 
protein kinases like protein kinase C in rodent mammary gland and an increased number of 
oestrogen receptor binding sites [149], (iii) increased prostaglandin concentrations. 
Prostaglandins, thromboxanes, leukotrienes and hydroxyperoxy and hydroxy fatty acids 
(collectively referred to as eicosanoids) are produced by cyclooxygenases and 
lipoxygenases and are involved in tumor initiation and promotion, cell proliferation, tissue
invasion and metastatic spread. Tumor cells produce la
 
 
  
 
  
 
 
  
  
 rger amounts of eicosanoids than 
eir normal cell counterparts and eicosanoids ultimately derived from arachidonic and 
noleic acid (ω-6 eicosanoids) have been linked to increased growth and metastasis. The 
nding that oleic acid and ω-3 PUFAs, specifically eicosapentanoic acid, block the desaturase 
action, the first step from linoleic acid to eicosanoids, may partially explain their inhibitory 
ffects on tumorigenesis. Indeed, a stepwise reduction in eicosapentaenoic acid 
oncentration was seen in diseased mucosa from benign adenoma to the most advanced 
 : ω-6 ratio may participate in the early 
hases of human carcinogenesis [150]. 
th
li
fi
re
e
c
colon cancer, indicating that a decline in the ω-3
p
 
2.2 Eicosanoid biosythesis 
 
The oxidative metabolism of arachidonic acid through cyclooxygenase, lipoxygenase, or 
P450 epoxygenase pathways leads to the formation of various bioactive eicosanoids. In 
mammalian cells, eicosanoid biosynthesis is usually initiated by the activation of 
phospholipases A2 and the release of arachidonic acid (AA) from membrane phospholipids. 
Cyclooxygenases (COXs) and lipoxygenase  (LOXs) subsequently transform AA into 
prostaglandins, thromboxane, and leukotrienes. Eicosanoid production is considerably 
increased during inflammation. Both COX and LOX pathways are of particular clinical 
relevance. The COX pathway is the major target for NSAIDs, the most popular medications 
used to treat pain, fever, and inflammation. Although, their anti-inflammatory effects are well 
known, their long-term use is associated with gastrointestinal (GI) complications such as 
ulceration of the gastric epithelium. In 1991, it was discovered that COX exists as two distinct 
isozymes, COX-1 and COX-2, of which COX-2 is the inducible i oform expressed at sites of 
 
s
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inflammation and produces pro-inflammatory eicosanoids. For this reason, COX-2 selective 
inhibitors (COXibs) have been developed as anti-inflammatory agents to minimize the risk of 
GI toxicity which is known to be primarily caused by COX-1-derived prostaglandins. 
ecently, some COX-2 selective inhibitors have shown adverse cardiovascular side-effects, 
resulting in the withdrawal of rofecoxib and valdecoxib from the market. [151].  
R
 
2.3 Lipoxygenases 
 
Lipoxygenases (LOXs) are a family of monomeric non-heme, non-sulfur iron ioxygenases, 
which catalyse the conversion of polyunsaturated fatty acids into conjugated hydroperoxides. 
Unsaturated fatty acids are absent in most bacteria and thus LOXs are also absent in typical 
prokaryotes. LOXs are widely expressed in plant and animal cells, sometimes at high level, 
and their activity may initiate the synthesis of signaling molecules or may induce structural or 
metabolic changes in the cell membrane. Mammalian LOXs have been implicated in the 
pathogenesis of several inflammatory conditions such as arthritis, psoriasis and bronchial 
asthma [152]. They are also thought to have a role in atherosclerosis, brain aging, HIV 
infection, kidney disease and cancer. In plants, LOXs favour germination, participate in the 
synthesis of traumatin and jasmonic acid, and are involved in the response to abiotic stress 
[153]. The phylogenetic tree shows that plant and animal LOXs are separate branches, each 
forming several subgroups [154].  
 
 
 
 
 d
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4: The phylogenetic tree of mammalian lipoxygenases 
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When arachidonic acid (AA) is the substrate, different LOX isozymes can insert molecular 
oxygen at carbons 5, 8, 12 or 15. Accordingly, they are designated 5-, 8-, 12- or 15-
lipoxygenases [152, 155-159]. The primary products are 5S-, 8S-, 12S-, or 15S-
ydroxyperoxyeicosatetraenoic acids (5-, 8-, 12-, or 15-HPETE), which are reduced by 
lutathatione peroxidase to the corresponding hydroxy forms (5-, 8-, 12-, or 15-HETE) or 
etabolized to hepoxilins, lipoxilins or leukotrienes. Linoleic acid (LA) and linolenic acid are 
lso substrates of LOXs. 
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Fig 5: Metabolism pathway of arachidonic and linoleic acid 
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The generation of LOX-derived metabolites is under a complex set of controls: Firstly, their 
synthesis from AA is initiated by cytosolic phospholipase A2 (cPLA2). cPLA2 is calcium-
dependent and is translocated to the nuclear membrane in several cells stimulated with IgE 
or the calcium ionophore A23187 [160]. Another critical aspect of LOXs control is its 
capability to bind proteins (e.g. 5-LOX binding the five-LOX-activating-protein FLAP). 
Phosphorylation via MAPK-activated protein kinase-2 is critical in controlling targeting and 
activation of these enzymes [161]. Therefore, the activation of LOX activity is generally rapid 
and transient, a property that is well adapted to their role in infection or injury, which needs 
urgent and time-limited generation of proinflammatory molecules. A constitutive LOX 
expression, on the other hand, seems to be involved in the pathogenesis of several 
diseases, including asthma [162], ulcerative colitis [163], psoriasis [164], artherosclerosis 
[165, 166], and cancer [166]. The constitutive LOX activity was shown to influence the 
proliferative rate of cells, their apoptosis resistance/sensitivity or their senescence response 
[167]. 
 
2.3.1 Lipoxygenase gene structure and chromosomal organisation 
humans, there exist six functional LOX genes and at least three pseudogenes.  The LOX  
enes are similar in size (7-21 kb) and lie on the short arm of chromosome 17 within a span 
f 3-4 Mb, with the exception of the 5-lipoxygenase gene which is much larger (82 kb) and is 
cated on the human chromosome 10q11.2. [168]. The genes of the epidermis-type LOX 
cluding 15-LOX-2, 12R-LOX and eLOX-3 are clustered within a short region of 100 kb on 
7p13.1 suggesting possible formation by gene duplication. The same genomic organisation 
f the epidermis-type LOX enzymes is also observed at the central region of mouse 
hromosome 11. 
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2.3.2 Lipoxygenase X-ray crystal structure 
 
LOXs consist of the N-terminal eight stranded anti-parallel β-barrel domain and the larger 
catalytic domain formed predominantly by α-helices (multi-colours). The β-barrel (dark blue) 
is not essential for catalysis; it is structurally related to the C2-like domains in lipases, and is 
thought to be implicated in membrane interactions and acquisition of substrate [169, 170].  
The catalytic C-terminal part contains the catalytic iron, and four highly conserved histidine 
residues and a C-terminal isoleucine which bind the central iron atom. The iron ligands are in 
an octa ce to allow for the 
pproach of substrate [171]. 
g 6: h-15-lox [98] 
ttp://www.dkfz.de/spec/lox-db/gallery. 
hedral arrangement with one position “open” and with sufficient spa
a
Fi
h
 
 
 
 
 
 
 
 
 
 
Introduction 
 
 - 24 – 
2.3.3 The substrate-product transformation  
 
A fundamental principle of LOX catalysis is that the reaction is initiated by stereospecific 
removal of a hydrogen from the CH2 group between two cis double bounds, and is completed 
by the insertion of O2 into the position +2 or -2 on the opposite face of the removed hydrogen 
[172]. This antarafacial relationship between hydrogen abstraction and oxygenation is a 
universal facet of LOX catalysis, counting for the synthesis of R or S  hydroperoxide products 
[173, 174]. Coffa et al described a model that can rationalize all known possibilities, where 
the more superficially located end of the reacting pentadiene is always associated with R 
chirality oxygenation, whereas S chirality oxygenation always occurs on the end of the 
pentadiene, lying deeper in the active site pocket. 
Some individual LOX enzymes synthesize two regioisomeric hydroperoxide products. 
Prototypical examples of such dual positional specificity LOXs are the enzymes 15-LOX-1 
and the  “leukocyte-type” 12-LOX [175, 176]. 
 
2.3.4 15-lipoxygenase-1 
 
15-LOXs can be sub-classified according to their enzymatic characteristics and specificty of 
tissue distribution into 15-LOX-1 and 15-LOX-2. 15-LOX-1 is expressed in reticulocytes, 
acrophages, tracheobronchial epithelial cells, skin, and colon [177, 178] and 
to 13(S)-hydroxyoctadecadienoic acid (13-HODE) and 
acid to 15(S)-hydroxyeicosatetraeonic acid (15-HETE), respectively [179]. On 
other hand, 15-LOX-2 expression is detected in skin, prostate, lung, , and cornea but not 
colon [180], and it preferentially converts arachidonic acid but also linoleic acid. The 
nzyme has been proposed to be involved in various physiological and pathophysiological 
ctivities such as inflammation, atherosclerosis, cell maturation, and tumorigenesis          
81-183].  
stimulate the expression of 15-LOX-1 through activation of the transcription factor 
Additional mechanisms for transcriptional controlling of 15-LOX expression involve 
s the promoter region of the 15-LOX-1 gene is GC-rich [56, 182, 184]. 
15-LOX-1 enzyme generating oxidative stress 
r the following reasons: (i) unlike other groups of mammalian LOXs, this enzyme is capable 
eosinophiles, m
converts linoleic acid preferentially 
arachidonic 
the 
in 
e
a
[1
Cytokines 
stat6. 
promoter methylation a
furthermore can be regarded as a prooxidant 
fo
of catalysing enzymatic lipid peroxidation in biomembranes and lipoproteins, (ii) it is a source 
of free radicals which can in turn initiate non-enzymatic lipid peroxdation and other harmful 
oxidative processes, (iii) LOX-catalysed reactions are favoured when the hydroxyperoxide 
tone of the cells is increased [185]. 
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2.3.5 Physiological functions of lipoxygenases  
 
Role of  LOX in inflammation:  
 
A) proinflammatory: 5-LOX products such as the leukotrienes (LTs) are components of a 
proinflammatory cascade. LTB4 is a  potent chemoattractant for neutrophils, eosinophils, 
monocytes. Cysteinyl LTs are potent bronchoconstrictors 
) anti-inflammatory:  Lipoxins and the recently discovered derivatives of omega-3 PUFAs, 
the  r are important mediators during the resolution phase of 
flammation controlling duration and magnitude of the inflammatory reaction [186]. 
B
esolvins and protectins 
in
 
 
Role of LOX in apoptosis: 
 
LOX products have been shown to induce programmed cell death (P i human T-cells 
[187], neutrophils [188], PC12h cells [189], and Jurkat cells [190]. Several studies have 
shown the proapoptotic activity of 5-LOX [191, 192], of leukocyte type 12-LOX [193, 194], 
and of 15-LOX-1 [178, 195] and have identified molecular targets for LOX-mediated induction 
of apoptosis. However, also anti-apoptotic effects of LOXs have been reported, mainly based 
on the observation t LOX inhibitors, most often ydroguaiaret acid (NDGA) and 
MK886, exh
CD) n 
tha nordih ic 
ibited pro-apoptotic activity [46, 196-198]. Interestingly, in other cellular types 
NDGA or MK886 protected against apoptosis [191, 194, 195, 199-202], or induced PCD in 
cell types completely devoid of LOX activity [203-205].  
 
2.3.6 Lipoxygenases and cancer 
 
LOXs have been found to be expressed in some types of cancer cells/tissues, including 
colon, lung, pleural, breast, prostate, bone, brain, skin, and pancreas [206-210], and their 
aberrant activity has been associated with several spects of tumorigenesis, including 
stimulation of cancer-cell proliferati
a
on, induction of genotoxicity, suppression of apoptosis, 
nd increased tumor angiogenic and metastatic potentials. HETEs can activate certain 
isoforms by incorporating into membrane 
which  then generate HETE-containing diacylglycerol species to activate PKC 
everal MAPKs and thereby activate key transcription factors 
stimulate DNA synthesis and proliferation of cancer cells (Ding 2003). Some LOXs 
a
of protein kinase C (PKC) directly or indirectly 
phospholipids, 
[165]. They can also activate s
that 
metabolites (e.g. 15-HETE) have also been shown to directly stimulate the transcription of 
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target genes apparently via activation of nuclear receptors, such as peroxisome-proliferator-
activated-receptors (PPARs) [211]. 
Human cancer tissues display an enhanced expression of 5-LOX and 12-LOX. At least for 
uman prostate, lung and pancreatic cancer, very low or undetectable 5-LOX as well as 12-
in normal cells or tissues, whereas high levels of 5-LOX as well 
12-LOX expression and activity are detected in corresponding transformed tissues [208, 
Blockade 
prosta
development, however, is unclear 
nd controversial [166]. Several studies suggest that the 15-LOX-1 product, 13-HODE 
enhanced 13-HODE enhanced cell proliferation and 
the mitogenic response to EGF in different cell types [218, 219]. Yoshinaga et al 
ssion o n
r lorecta
h
LOX expression is observed 
as 
212, 213]. 5-LOX inhibitors have chemopreventive effects in animal lung carcinogenesis 
[214]. of 5-LOX inhibits prostate cancer cell proliferation while 5-HETE stimulates 
prostate cancer cell growth [215]. Furthermore, the FLAP inhibitor, MK886 exerts similar 
growth inhibitory effects on cancer cell proliferation to 5-LOX enzyme inhibitors [216]. 
Similar effects were observed for 12-LOX inhibitors which induced apoptosis whereas 12-
HETE prevented apoptosis in te cancer cells [217]. Intriguingly, the degree of 12-LOX 
expression in human prostate cancer correlated with the tumor grade and stage, i.e. 12-LOX 
expression level is higher in metastatic prostate cancers than in nonmetastatic ones [212]. 
The role of 15-LOX-1 expression and activity in cancer 
a
colonic tumorigenesis. Moreover, 
potentiated 
reported that over-expre f 15-LOX-1 i duced extracellular signal-related kinase 1/2 
(ERK1/2) phosphorylation, decreased p21 (cip/WAF1) expression, and increased colon 
cancer cell growth [220]. Eling et al reported that the anti-proliferative effect of 15-LOX-1 in 
colorectal cancer cells was associated with phosphorylation of p53 [221]. In contrast, 
Lippmann et al eported that 13-HODE enhanced apoptosis and cell cycle arrest in co l 
cancer cells [222]. 
These data suggest that distinct LOXs, the expression of which is lost during progression of 
cancer, may exhibit antitumorigenic activities, while other isoforms that are preferentially 
expressed during carcinogenesis may exert protumorigenic effects. 
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2.4 Aim 
 
Pancreatic cancer is the tenth leading cancer disease in men and the ninth leading in 
women. Because of late diagnosis it is the fourth leading cause of cancer death in male and 
the fifth leading cause of cancer death in women. Numerous clinical data on LOX expression 
in human tumors and in animal models indicate a antipodal role of LOX metabolism in 
carcinogenesis. In fact, different LOX isoforms exhibit either pro-tumorigenic or anti-
tumorigenic activities and modulate the tumor response in a tissue-specific manner. The data 
suggest that the 5- and platelet-type 12-lipoxygenase exhibit pro-carcinogenic activities.   
In contrast, 15-LOX-1 is down-regulated in human esophageal, gastric, colorectal and breast 
carcinomas. In the past, conflicting data on 15-LOX-1 expression in colorectal carcinomas 
were published since one group described elevated levels of 15-LOX-1 in human colon 
tumors. To date, nothing is known about the role of 15-LOX-1 in pancreatic cancer. 
Therefore, in the present study the expression of 15-LOX-1 in normal and pathologic 
pancreatic tissues and the effect of 15-LOX-1 expression on pancreatic cancer cell 
proliferation will be investigated, as well as cell cycle analysis and measurement of apoptosis 
will be performed. Further, the effect of both, substrates and products, on cell proliferation 
will be analyzed.  
In addition, different HDAC inhibitors will be used to restore 15-LOX-1 expression in 
pancreatic cancer cell lines and cell proliferation will be determined. 
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B: Materials and methods 
 
3. Materials  
 
3.1 Equipment, apparatures 
 
-80°C freezer     Heraeus AG, Zürich, Switzerland 
-20°C freezer     Liebherr; Ochsenhausen  
37°C, 5% CO2 incubator    Sanyo Scientific, Bensenville, IL, USA  
4°C fridge     Liebherr, Ochsenhausen  
Analysis balance    Labtronics Inc., Gouda, Netherlands 
Autoclave Vakulab HP   Medizin Mechanik GmbH München 
Balance BL 6100    Zeiss, Goettingen 
Bio-photometer    Eppendorf AG, Hamburg   
Centrifuge Z33M    Hermle, Wiesloch 
CO2 incubator     Sanyo Scientific, Bensenville, IL, USA  
Dynal sample mixer    Invitrogen, Karlsruhe 
Guava PCA     Guava Technologies, Hayward, CA, USA 
Heating water bath    Lauda, Groton, CT, USA 
Ice machine     West End Lumber, Lorain, CL, USA 
Kodak biomax x-ray cassette  Eastman Kodak Company, Rochester, USA 
Magnet stirrer     Jahnke & Kunkel , Staufen i. B 
Magnet particle concentrator (MPC)  Invitrogen, Karlsruhe, germany 
Microplate Elisa reader    Thermo Electron GmbH, Karlsruhe 
Microscope     Leica, Bensheim 
Microwave     Quelle, Fürth 
Nano-Drop     Kisker-Biotech, Steinfurt 
NuPage western apparatus   Invitrogen, Karlsruhe 
pH-analyser pH 330    Fischer BioBlock Scientific, Illirch Cedex 
Power supply     Biotec Fischer, Reiskirchen 
Shaker      Heidolph, Darmstadt 
Shaker for Western Blot analysis   Neolab, Heidelberg 
Sterilgard Hood     Kojair, Uilppula,  Finland 
Table centrifuge    Eppendorf, Hamburg 
Ultrasound, sonoplus    Bandelin, Berlin  
Vortex                Heidolph, Schwallbach  
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Water filter system    Millipore, Schwallbach 
Water bath     Köttermann, Uetze/Hänigsen 
x-ray developer    Protec, Oberstenfeld 
 
3.2 Plastic- and glas ware  
 
24-well plates     Greiner, bio-one, Frickenhausen 
50 ml/ 15 ml Falcontubes   Greiner, bio-one, Frickenhausen 
96-well plates     Greiner, bio-one, Frickenhausen 
Bis-Tris gels (10%)    INVITROGEN, Karlsruhe 
Blotting Paper     Schleicher & Schuell, Dassel 
Cell culture flasks (T25, T75)   Greiner, bio-one, Frickenhausen  
Cell scraper     Greiner, bio-one, Frickenhausen 
Collagen I type 60mm dishes  Greiner, bio-one, Frickenhausen 
Eppendorf® 1,5ml Tubes   Eppendorf AG, Hamburg 
Films for western    Fujifilms, Germany 
filter tips     CLP, San Diego, CA, USA 
Multistepper      Eppendorf, Hamburg  
Nitrocellulose membrane   BioRad, Hercules, CA, USA 
Parafilm     Pechiney plastic packaging, Chicago, USA 
Pasteur pipettes plastic   BD Biosciences, Heidelberg  
PCR- tubes       Brand, Wertheim  
Petridishes     BD Bioscience, Heidelberg 
Pipetman®     
(1000 µl, 200 µl, 20 µl, 10 µl)   Gilson, Bad Camberg 
Pipettus     Hirschmann, Eberstadt 
Plastic cuvettes    Eppendorf, Hamburg 
Plastic pipettes Cellstar® 10ml  Greiner, bio-one, Frickenhausen 
Plastic pipettes Costar®   
(2 ml, 5 ml, 25 ml)    Corning Inc., Corning, NY, USA 
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3.3 Chemicals
 
Aceton, HPLC-grade    Fischer Scientific, Leicestershire,UK 
Acetic acid, HPLC-grade   Fluka, Neu-Ulm     
Agarose     Sigma-Aldrich, München 
Aprotinin      Sigma-Aldrich,  München 
ε-Amino-n-Capronsäure   Sigma-Aldrich,  München 
β-mercaptoethanol    Sigma-Aldrich, München 
Arachidonic acid    Cayman Chemicals, Michigan, USA 
Boric acid     CALBIOCHEM (Merck KG), Darmstadt 
Bovine serum albumin, BSA   Roth, Karlsruhe  
Carbenicillin     Hybaid, Heidelberg 
Chloroforme     J.T. Baker, Deventer, Netherlads 
Dichlormethan, HPLC-grade   Roth, Karlsruhe 
Dimethylsulfoxid               Sigma, Taufkirchen 
DL-Dithiothreitol, DTT    Sigma-Aldrich, München 
Dynabeads Pan Mouse IgG   Invitrogen, Karlsruhe 
4-(2-hydroxyethyl)-1-piperazin-  
ethanesulfonic acid, HEPES   Sigma-Aldrich, München 
Ethanol, HPLC-grade    Merck Biosciences, Schwalbach 
Ethanol, EtOH (96%)    Roth, Karlsruhe 
Ethidium bromide, EtBr   Merck, Darmstadt 
Ethylenediaminetetraacetic  
acid, EDTA     Roth, Karlsruhe 
Glycerin     Merck Biosciences, Schwalbach 
Glycin      Roth, Karlsruhe 
H2O (MQ)     Millipore, Schwallbach 
Hematoxylene     Merck, Darmstadt 
15-S-HETE     Cayman Chemicals, Michigan, USA 
13-S-HODE     Cayman Chemicals, Michigan, USA 
Hydrochlorid acid, HCl   Merck, Darmstadt 
Hydrogen peroxide, H2O2    Roth, Karlsruhe 
Leupeptin     Sigma-Aldrich,  München 
Linoleic acid     Cayman Chemicals, Michigan, USA 
Luria-Agar     Gibco, Karlsruhe 
Luria-Broth base    Gibco, Karlsruhe 
Magnesium chloride, MgCl2                Merck, Darmstadt 
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Methanol, MeOH     Roth, Karlsruhe 
Methanol, HPLC-grade   Roth, Karlsruhe   
Milk powder     Fluka, Neu-Ulm 
Phosphate buffered saline (PBS)  Biochrome AG, Berlin 
Sodium hydroxide     Merck, Darmstadt 
Tris      Roth, Karlsruhe 
Tween-20      Merck Biosciences, Schwallbach 
 
3.4 Kits 
 
BCA protein assay kit    Pierce, Rockford, USA 
cDNA Synthesis Kit    Roche, Mannheim 
GUAVA Check kit     Guava Technologies, Hayward, CA, USA 
GUAVA Nexin kit    Guava Technologies, Hayward, CA, USA 
GUAVA ViaCount kit    Guava Technologies, Hayward, CA, USA 
Lipofectamine2000    Invitrogen, Karlsruhe 
RNeasy kit     Qiagen, Hilden 
RQ1 RNase-Free DNase   Promega, Mannheim 
WST-1 assay     Roche, Mannheim 
 
3.5 Primary antibodies
 
15-LOX-1 anti serum    Roche (M.Mulkins), Bioscience, CA, USA 
CD90 fibroblast    Invitrogen, Karlsruhe 
KAI  1      Santa Cruz, CA, USA 
S100A4     Dako, Hamburg 
Phospho p42/44    Cell signaling, MA, USA 
P42/44     Cell signaling, MA, USA 
Phospho MEK1/2    Cell signaling, MA, USA 
MEK1/2     Cell signaling, MA, USA 
 
3.6 Secondary Antibodies 
 
Goat-anti-rabbit    Santa Cruz, CA, USA 
Donkey-anti-mouse    Santa Cruz, CA, USA 
Donkey-anti-goat    Santa Cruz, CA, USA 
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3.7 Ladders 
 
PageRuler™ #SM0671,  
Prestained protein ladder   Fermentas, St. Leon-Rot 
1kB DNA ladder    Fermentas, St. Leon-Rot 
 
Bacteria 
 
One ShotTM TOP10 (E.coli)   Invitrogen, Karlsruhe  
 
3.8 Reagents and buffers for western blot analysis     
 
ECL reagent for western   Amersham Biosciences, Freiburg 
LDS sample buffer    INVITROGEN, Karlsruhe 
MES SDS Running buffer   INVITROGEN, Karlsruhe 
Reducing agent    INVITROGEN, Karlsruhe 
Stripping buffer     (see 2.2.6) 
Transfer buffer    INVITROGEN, Karlsruhe 
PBST       (see 2.2.6) 
PBSM       (see 2.2.6) 
 
3.9 PCR reagents
 
Buffer (10x) cont. MgCl2   QBIOgene, Illkirch, France  
dNTP’s (10mM)    QBIOgene, Illkirch, France 
H2O      Millipore, Schwallbach 
Primer (see table 3)     Invitrogen, Paisley, Great Britain 
Taq-Polymerase    QBIOgene, Illkirch, France 
 
3.10 Reagents for electrophoresis 
 
Loading dye     Fermentas, St. Leon-Rot 
TBE buffer      (see 2.2.4) 
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3.11 Cell culture 
 
0.25% Trypsin-EDTA    INVITROGEN, Karlsruhe 
DMEM (4500 mg/ml Glucose)  GIBCO, Karlsruhe 
EMEM 
RPMI 1640 medium    GIBCO, Karlsruhe 
Dulbecco’s PBS-/-    PROMOCELL, Heidelberg 
FBS      PAN Biotech, Aidenbach 
Penicillin-streptomycin solution  GIBCO, Karlsruhe 
Sodium pyruvate solution (100 mM)  GIBCO, Karlsruhe 
 
3.12 Cell lines 
 
Tab 1: Cell lines used in this study described by source, histology and grade of the primary tumor. 
Name Source of tumor cells Histology and grade of primary tumor 
AsPC-1 Ascites PDAC, G2 
Capan I liver metastasis PDAC, G1 
Capan II primary tumor PDAC, G1 
MiaPaCa2 primary tumor PDAC, G3 
Panc-1 primary tumor PDAC, G3 
S2-O13 Liver metastasis   
SU8686 Liver metastasis PDAC, G2/ G3 
T3M4 (Panc-89) lymph node metastasis PDAC, G2 
HEK 293 Human embryonic kidney  
normal ductal cells pancreas donor  
 
3.13 Software 
 
Microsoft ® Excel 2003   Microsoft Corp, Albuquerque, NM, USA 
Microsoft ® PowerPoint 2003  Microsoft Corp, Albuquerque, NM, USA 
Microsoft ® Word 2003    Microsoft Corp, Albuquerque, NM, USA 
NanoDrop 3.1.0    Coleman Technologies Inc., MO, USA 
EndNote X.0.2    Thomson ResearchSoft, CA, USA 
Millenium HPLC software   Waters, MA, USA 
World Wide Web    www.google.com
      www.ncbi.nml.nhi.gov
      www.pathology.jhu.edu
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4. Methods 
 
4.1 DNA preparation and isolation 
 
4.1.1 Transformation of competent cells 
 
50 µl competent cells (One ShotTM TOP10) were thaw rapidly, mixed with 1 µl DNA (50 ng/µl) 
and placed on ice for 10 min. Heat shock was carried out by placing tubes into a 42°C water 
bath for 45 sec and then incubated on ice for 2 min. 900 µl SOC medium were added to each 
tube and placed in a shaker at 250 rpm for 1 hour at 37°C. Finally the mix was plated on 
carbenicillin containing LB plates. Colonies were grown for 12-16 hours at 37°C. 
  
4.1.2 DNA isolation 
 
A single colony from a freshly streaked selective plate was picked and a starter culture of    
2–5 ml LB medium containing the appropriate selective antibiotic was inoculated and 
incubated for approx. 8 h at 37°C with vigorous shaking (approx. 300 rpm). The starter 
culture was diluted 1/500 to 1/1000 into selective LB medium. The bacterial cells were 
harvested by centrifugation at 6000 x g for 15 min at 4°C.  The bacterial pellet was 
resuspended in 10 ml Buffer P1. 10 ml Buffer P2 were added, and mixed thoroughly by 
vigorously inverting and incubated at room temperature for 5 min. 10 ml chilled Buffer P3 
were added to the lysate, and mixed immediately and 
thoroughly by vigorously inverting 4–6 times. The lysate was poured into the barrel of the 
QIAfilter Cartridge and incubate at room temperature for 10 min. The QIAGEN-tip 500 were 
equilibrated by applying 10 ml Buffer QBT. The cell lysate was filtered into 
the previously equilibrated QIAGEN-tip. The cleared lysate was allowed to enter the resin by 
gravity flow. The QIAGEN-tip was washed with 2 x 30 ml Buffer QC. DNA was eluted 15 ml 
Buffer QF and precipitated by adding 10.5 ml (0.7 volumes) room-temperature isopropanol. 
Finally  mixed and centrifuged immediately at ≥15,000 x g for 30 min at 4°C, the supernatant 
was decanted carefully. The DNA pellet was washed with 5 ml of room-temperature 70% 
ethanol, and centrifuged at ≥15,000 x g for 10 min. The supernatant was decanted carefully. 
The pellet was air-dried for 5–10 min, and re-dissolved in a suitable volume of EB-buffer.  
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4.1.3 Restriction analysis
 
Isolated DNA was analyzed by restriction enzymes. For the 15-LOX-1 plasmid (2042) Bg1II 
and EcoRI were used. The final mix contained 1 µl buffer H, 0,5 µl of each enzyme, 1 µl DNA 
and 7 µl H2O. The mix was incubated for 1 hour at 37°C and then analyzed on an agarose 
gel. 
 
4.2 RNA isolation and cDNA preparation 
 
4.2.1 RNA isolation 
 
Total RNA from all cultured cell lines was isolated using the RNeasy Kit. Cells were seeded 
in 10 cm dishes and grown to 90% confluence. Before starting, 10 µl of β-mercaptoethanol 
was added to 1 ml RLT buffer (RLT*). Then medium was aspirated and 350 µl RLT* buffer 
were added to each 10 cm dish. Cells were scraped and pipetted into a 1.5 ml Eppendorf 
tube. Afterwards the lysates were passed at least 5 times trough a needle (0.9 mm diameter) 
fitted to an RNase-free syringe. 350 µl EtOH (70%) were added, mixed well and the lysate 
pipetted onto RNeasy columns placed in a 2 ml collection tube. After centrifugation at room 
temperature (RT), for 15 s at 10,000 rpm, the flow through was discarded and 700 µl of RW1 
buffer were added and the columns centrifuged again. The column was now placed in a new 
collection tube and centrifuged again. After this step 500 µl RPE buffer were added and the 
columns centrifuged for 15 s at 10,000 rpm. Then again 500 µl RPE buffer were added and 
the columns were centrifuged for 2 min at 10,000 rpm. The flow-through was discarded and 
the columns centrifuged for 1 min at 13,200 rpm. Finally the columns were placed in 1.5 ml 
tubes and 40 µl of RNase-free water were added directly onto the membrane in the column 
and centrifuged for 1 min at 10,000 rpm. This step was repeated using the flow through.  
Concentration of cDNA in aqueous solutions was measured using the NanoDrop 
spectrophotometer. 1 µl of each sample was pipetted onto the reading area. Absorption was 
measured at 260 nm against EB-buffer which served as reference. Simultaneously 
absorption at 280 nm was measured and the ratio A260/ A280 was calculated. The ratio gives 
the purity of each sample. Normal values for DNA are between 1.8 and 2. For DNA free RNA 
the ratio should be between 1.9 and 2.1. 
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4.2.2 Reverse transcriptase-PCR 
 
To ensure purity, isolated RNA was treated with DNase I to get rid of contaminating genomic 
DNA. Final reaction volume was 10 µl, containing 3 µg RNA, 3 µl DNase I,  1 µl reaction 
buffer and MQ-H2O. The mix was incubated at 37°C for 30 minutes, afterwards 1 µl of stop 
solution was added and incubated at 65°C for 10 min. 
The isolated RNA was reverse transcribed into cDNA. The total reaction volume was 21.8 μl: 
10 µl DNase I treated total RNA, 2 µl reaction buffer, 2 µl MgCl2, 2 µl dNTP-Mix, 2 µl Oligo-
p(dN)6 Primer, 1 µl RNase Inhibitor, 0.8 µl AMV reverse transcriptase and 2 µl 
RNase/DNase-free H2O. The thermocycler protocol for the RT-PCR is: one cycle at 25°C for 
10 min, 42°C for 60 min, one cycle at 99°C for 5 min and one last cycle at 4°C for 5 min (see 
fig. 13). 
    
Fig 6: Reaction profile of a reverse transcription polymerase chain reaction. 
 
4.2.3 Electrophoresis for 15-LOX-1 and actin 
 
Polymerase chain reaction (PCR) is used to amplify a region of cDNA to identify the mRNA 
expression level of a gene. 
For amplifying mRNA of interest, first primers have to be constructed which are specific. After 
this the melting temperature (Tm) is calculated with following formula:  
Tm = 2 . (A + T) + 4 . (G + C) 
It is proposed to use a Tm about 3 - 5°C below the calculated temperature. 
Of the obtained cDNA 1 µl was used for 15-LOX-1 PCR using specific primers (see Tab. 4). 
These primers amplify a region which is specific for the protein that is encoded by the 
corresponding gene. 0.1 µl Taq-polymerase, 2.5 µl dNTP’s (2.5 mM), 2.5 µl MgCl2 (50 mM), 
2.5 µl reaction buffer(10x), 1 µl (10 pM) primers and x µl MQ-H2O and 1 µl cDNA were used 
up to 25 µl.  
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The PCR profile was 1 cycle at 95°C for 5 min; 94°C for 1.5 min; 56°C, 1.5 min and 72°C, 2.5 
min for 36 cycles and one cycle at 72°C for 10 min the final step is the incubation at 4°C (see 
fig. 6). 
   
Fig 7: Reaction profile of polymerase chain reaction to detect 15-LOX-1 mRNA in pancreatic cancer cell lines 
 
The final PCR product was separated on 1% agarose gel containing 0.00001% ethidium 
bromide (10 mg/ml).  For this 1.0 g of agarose were solved in 100 ml of 1x TBE buffer (10x 
TBE: 2.5 M Tris, 2.22 M boric acid, 0.32 g EDTA, ad MQ-H2O to 1000 ml), boiled in a 
microwave and after slight cooling EtBr was added. The mixture was then allowed to cool 
down in a gel mould with combs to produce the pockets. After polymerisation combs were 
removed and the gel was set into an electrophoresis chamber and submerged with 1x TBE 
buffer. 1 µl loading dye was added to the samples and 10 µl of each sample and 8 µl of the 
100bp DNA ladder were pipetted into each pocket. The electrophoresis was carried out at a 
voltage of 100 V for 1 hour. The PCR product was visualized using UV light and 
photographed. 
 
Tab 2 : Specific primers 
 5’ Primer 3’ Primer Product 
size 
15-LOX-1 
(human) 
5'- CATCTATCGGTATGTGGA -3' 3- GAAGTTGGGCAGTGTC -5' 340 bp 
β-actin 
(human) 
5'- CTTCCTGGGCATGGAGTCCT -3' 3’- CCGCCGATCCACACAGAGTA -5' 182 bp 
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4.3 Cell culture  
 
4.3.1 Cell lines  
 
Pancreatic tumor cell lines including AsPC-1, Capan I, Capan II, MiaPaCa-2, Panc-1, 
SU8686 and T3M4 were established from patients with pancreatic adenocarcinoma and 
cultured in RPMI 1640 supplemented with 10% FBS and 1% Penicillin-streptomycin. S2-O13 
cell line was cultured in DMEM containing 10% FBS and 1% Pen/Strep. HEK293 cells were 
maintained in EMEM supplemented with 10% FBS, 1% Penicillin-streptomycin, and 1% L-
glutamine (200 mM). All cell lines except S2-O13 were purchased from the American Type 
Culture Collection (ATCC, Rockville, MA, USA). S2-O13 cells were provided by Dr. 
M.A.Hollingsworth (Eppley Cancer Institute, Omaha, NE, USA). 
Cells were grown as monolayers in a humidified atmosphere of 5% CO2 at 37°C. Adherent 
cells were detached by trypsinisation with 1 ml trypsin-EDTA solution for a T75 flask after 
washing with 5 ml PBS. Cells were cultured in a volume of 10 ml in T75 flasks. For petri-
dishes (d = 10 cm) 3 ml PBS and 0,5 ml trypsin-EDTA solution were used and the final 
volume of medium was 10 ml. 
 
4.3.2 Ductal cell isolation 
 
After obtaining the ethical approval, normal ducts isolated from patients were cut into 1-2 mm 
pieces and plated onto collagen I coated 60 mm dishes. After 5 to 6 days the tissue pieces 
were removed and medium was replaced. To remove interfering fibroblasts dynabeads (DB) 
were used. Before starting the beads were coupled to the fibroblast antibody CD92. 
Dynabeads (1 ml) were resuspended in 1 ml PBS and then placed in the magnetic particle 
concentrator (MPC) for 2 min. This step was repeated twice and the beads finally were 
resuspended in 1 ml PBS. Per 25 µl DB 1 µg primary antibody were used. After adding the 
antibody to the beads the mix was incubated for 1 hour at 18-25°C gently tilting and rotating. 
After applying to the MPC the supernatant was discarded. The beads were resuspended in 2 
ml PBS and again placed on the MPC. Finally, the beads were mixed into 1 ml PBS. At least 
4 DB per targeted cell and > 1 x 107   (25 µl) beads were used. After trypsinization cells were 
incubated with the coated beads for 30 min at 4°C gently tilting and rotating. The tube was 
afterwards placed in the MPC and left there for 2-3 min. Finally, the purified ductal cells, 
comprised in the supernatant, were placed onto collagen I coated 60 mm dishes. 
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4.3.3 Stable transfection 
 
The plasmids of pcDNA3.1 and pcDNA3.1-15-LOX-1 containing the coding region of human 
15-LOX-1 were transfected into MiaPaCa2 and S2-O13 cells according to the manufacturer’s 
protocol using Lipofectamine2000 (Invitrogen, Karlsruhe, Germany).  
One day before transfection 2 x 106 cells were seeded in 10 ml of growth medium into        
100 mm dishes. At 90% confluence medium was replaced by 15 ml medium without serum. 
24 µg DNA were diluted in 1.5 ml serum-free medium and mixed. 60 µl Lipofectamine2000 
were mixed with 1.5 ml serum-free medium and incubated for 5 min at RT. After incubation 
Lipofectamine2000 mix was added to the DNA mix and incubated for 20 min at RT. The 3 ml 
of complexes were added to the plate. 
After 24 hours fresh medium was added to the cells containing the selection reagent G418 
(100 µg/ml). Selection was continued for one week, with the medium being refreshed every 
alternate day. After one week cells were maintained at 20 µg/ml G418. Clones were isolated 
and 15-LOX-1 over-expression was confirmed by western blot analysis and activity assay. 
 
4.3.4 Transient transfection 
 
Transient transfection of HEK293 cells was carried out to generate  positive controls for 
western blot analysis. The plasmid of pcDNA3.1-15-LOX-1 containing the coding region of 
human 15-LOX-1 was transfected into HEK293 cells according to the manufacturer’s 
protocol using Lipofectamine2000 (Invitrogen, Karlsruhe, Germany).  
One day before transfection 2 x 106 cells were seeded in 10 ml of growth medium into 
100mm dishes. At 90% confluence medium was replaced by 15 ml medium without serum.    
24 µg DNA were diluted in 1.5 ml serum-free medium and mixed. 60 µl Lipofectamine2000 
were mixed with 1.5 ml serum-free medium and incubated for 5 min at RT. After incubation 
Lipofectamine2000 mix was added to the DNA mix and incubated for 20 min at RT. The 3 ml 
of complexes were added to the plate. After 24 hours the cells were washed with PBS and 
removed from the plate using a cell scraper and centrifuged for 10 min at 1200rpm at RT. 
The pellet was lysed in 500 µl lysis buffer (50 mM Tris pH 7.4; 1 mM EDTA;  1 mM EGTA;    
1 mM leupeptin) and sonicated 3 times 10 sec, using ultrasound. Protein concentration was 
measured using the BCA assay.  
MiaPaCa2 was transiently transfected with the pcDNA3.1-15-LOX-1 plasmid following the 
protocol described above. Proteins were isolated 1h, 6h, 24h, 48h, 72h, and 96h after 
transfection. As negative control non-transfected cells were used for western blot analysis.  
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4.5 Protein expression analysis 
 
4.5.1 Measurement of protein concentrations using BCA assay 
 
The protein concentration was measured using the BCA assay. Reagents A and B were 
diluted 50:1 and 200 µl of this were pipetted into each well of a 96-well plate. Four Standards 
were used (2 µg/µl, 1 µg/µl, 0.5 µg/µl and 0.25 µg/µl). 5 µl of each sample and standard were 
pipetted in duplicates. The plate was incubated at 37°C for 30 min and protein concentration 
was measured at 570 nm using a photometer and calculated using linear equation and a 
standard.  
In cases of low protein concentrations EtOH-precipitation or SpeedVac system were used to 
concentrate the proteins. For EtOH-precipitation 100 µl sample were diluted in  1 ml EtOH, 
incubated for 5 min in N2 liq, centrifuged at 13,000 rpm for 10 min and then dissolved in 25 µl 
MQ-H2O. After this, concentration was calculated according to the used µl of sample and 
MQ-H2O. Most often SpeedVac system was used to vaporize the water from the sample and 
get higher concentrated proteins. 
 
4.5.2 Western blot analysis for 15-lipoxygenase-1 (15-LOX-1) and MAPK 
 
Western blot analysis was carried out to determine the protein expression of 15-LOX-1 in 
pancreatic tumor cell lines. Proteins were prepared as mention above. 
The NuPAGE® System for Western Blot analysis is based upon a Bis-Tris-HCl buffered (pH 
6.4) polyacrylamide gel, with a separating gel that operates at pH 7.0. As NuPAGE® Novex 
Bis-Tris gels do not contain SDS, they are formulated for denaturing gel electrophoresis 
applications only. For this, samples were mixed with LDS sample buffer (lithium dodecyl 
sulfate) and reducing agent and denatured at 70°C for 10 min to unfold the proteins. DTT 
(dithiothreitol) which is comprised in the reducing agent prevents the reformation of disulfide 
bonds. LDS besieges the protein with a negative charge. In an electric field the proteins are 
moving towards the anode (+) and are separated by their molecular weight (mw).      
30 µg protein lysate of each pancreatic cancer cell line was mixed with 1 µl Reducing agent, 
2.5 µl LDS Sample Buffer and MQ-H2O up to 10 µl. 5 µl prestained protein ladder and 10 µl 
of each sample were separated by SDS-PAGE. MES buffer was used and an electric current 
of 200 V was applied for 35 min. Proteins were transferred to nitrocellulose membranes by 
electroblotting using a Nu-PAGE transfer blotting apparatus at 30 V for 2 hours. 
Nitrocellulose membranes were subsequently blocked in 1x PBS containing 5% non-fat milk 
and 0.05% Tween 20 (PBSTM) overnight at 4°C and then treated with 15-LOX-1 antibody or 
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the different MAPK antibodies (see table) diluted in PBSTM for 1 hour. After six times 10 min 
washing in PBSTM, the membranes were incubated with horseradish peroxidase (HRP) 
conjugated goat anti-rabbit antibody (1:2000) for 1 hour at RT. After 3 x 10 min washing with 
PBST, 15-LOX-1 expression was detected by ECL (enhanced chemiluminescence) 
treatment (1 min) and light emission was detected on a x-ray film after 30 min of exposure. 
To confirm equal loading the membrane was stripped in 0.2 M Glycin containing     0.05% 
Tween20 for 20 min at 80°C. After 1 hour blocking, membrane was incubated with the first 
antibody β-actin (1:5000) for 1 hour at RT. After 3 x 10 min washing and 1 hour blocking the 
membrane was incubated with HRP secondary anti-goat antibody for 1 hour. After 3 x 10 min 
washing detection was carried out as described above. 
 
Tab 3: List of used antibodies 
1. Antibody Dilution 2.Antibody Dilution 
15-LOX-1 1:10000 Anti-rabbit 1:2000 
Phospho p42/44 1:1000 Anti-rabbit 1:2000 
P42/44 1:1000 Anti-rabbit 1:2000 
Phospho MEK1/2 1:1000 Anti-rabbit 1:2000 
MEK1/2 1:1000 Anti-rabbit 1:2000 
Actin 1:2000 Anti-goat 1:2000 
 
4.6 LOX activity assays  
 
LOX activity was quantified by measuring HETE formation in cell-free protein extracts. 250 
µg cytosolic protein homogenates were incubated with 100 µM arachidonic acid for 15 min at 
37°C. The incubations were terminated by addition of 40 µl of 1 M sodium formate buffer (pH 
3.1) and products were extracted with a modification of the Bligh and Dyer procedure as 
described (36). Products were analyzed by Reverse-phase-HPLC on a 5 µm YMC-Pack 
ODS-AM column (25 x 0.46 cm, YMC Europe, Schermbeck, Germany) with a 1 cm guard 
column using the solvent system of methanol/water/acetic acid (82/18/0.01 by volume) and a 
flow rate of 0.5 ml/min. Elution was monitored at 236 nm with a Bio-Tek Kontron 540 diode 
array detector. The products were identified by comparing retention times and peak areas 
with those of authentic external 15-S-HETE standard (Reatec, Weiterstadt, Germany). The 
retention time for 15-S-HETE was 28.0 min. 
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4.7 Cell proliferation analysis 
 
4.7.1 WST-1 assay  
 
Cell proliferation was measured using the WST-1 assay. This is a tetrazolium salt which is 
cleaved by mitochondrial succinate dehydrogenase to build formazan. The overall activity of 
mitochondrial dehydrogenases is associated with cell viability. The more products are built 
the more proliferation takes place. The advantage of WST-1 in contrast to MTT, XTT or MTS 
is that the cleavage products are water soluble and can easily be measured. 1000 cells of 
each cell line were plated into six wells of four 96-well plates using 100 µl/well cell culture 
medium. For each treatment triplicates were carried out. After 24 hours treatment was 
started and proliferation measured, comparing treated vs solvent treated cells, 24 hours after 
induction up to 120. 72 hours after treatment medium was changed.10 µl of the ready-to-use 
WST-1 reagent were added every 24 hours up to 120 hours to the cells and incubated for 1 
hour at 37°C and 5% CO2 according to the manufacturer’s protocol. Absorbance was 
measured in a microplate reader at a wavelength of 450 nm.  
 
4.7.2 GUAVA ViaCount 
 
The GUAVA® PCATM is a desktop cell analysis system with a wide range of possible cellular 
assays like cell counting, viability, TUNEL assay, Multicaspase assay, Nexin assay, cell cycle 
analysis etc. GUAVA ViaCount analyzes the fluorescence of cells stained with the ViaCount 
reagent and quantitates the number of viable and non-viable cells in each sample. The 
ViaCount reagent contains DNA-binding dyes and stains viable and non-viable cells in a 
different way corresponding to their permeability to this reagent. Stained nucleated events 
are counted and the forward scatter properties are used to distinguish free nuclei and cellular 
debris from cells to determine an accurate cell count. 
Before starting experiments GUAVA Check was carried out with supplemented beads as 
described in the manufacturer’s protocol. At starting point 3 x 104 cells/ml for MiaPaCa2 and 
S2-O13 were seeded in triplicates into 6-well plates. After 24 hours cells were treated. 
Duplicates of each well were counted every 24 hours up to 120 hours using the GUAVA cell 
counter. 72 hours after treatment medium was changed. As negative controls the appropriate 
solvents served. 
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Proliferation assay setups: 
• Comparison of 15-LOX-1 vs moc transfected cells: 
50000 cells each were seeded into 60mm dishes with a final volume of 2ml. For each 
counting triplicates were performed. Proliferation was determined 24 hours up to 120 
hours after seeding without any further treatment. 
• Exogenous treatment with 15-LOX-1 substrates and products: 
15-LOX-1 and mock cells were seeded in serum-containing medium at a concentration of 
5 x104 cells into three 60mm dishes with a final volume of 2 ml. After 24 hours treatment 
was started in serum-free medium. 
• Treatment with HDAC inhibitors 
15-LOX-1 and mock cells were seeded in serum-containing medium at a concentration of 
5 x104 cells into three 60mm dishes with a final volume of 2 ml. After 24 hours treatment 
was started in serum-containing medium. 
• Treatment with caffeic acid 
Normal ductal cells were seeded in serum-containing medium at a concentration of 1000 
cells/ well into a 96 well plate. After 24 hours treatment was started in serum-containing 
medium. 
 
4.8  Apoptosis measurement 
 
4.8.1 Nexin Assay (Apoptosis Assay) 
 
In this assay cells can be differentiated in viable, early and late apoptotic cells. Also cell 
debris can be detected. The principle of this test follows the externalization of 
phosphatidylserine (PS) during apoptosis of cells. PS is normally localized on the inner side 
of the cell membrane and moves to the outer surface when cells undergo apoptosis. In late 
stages of apoptosis cell membranes loose their integrity and begin to brake down. Annexin V 
is a Ca2+ dependent phospholipid binding protein which binds PS with a high affinity when it 
is located on the outer surface of the cell membrane. Nexin 7-AAD is a viability stain and 
used as an indicator of membrane structural integrity in this assay. 7-AAD binds to nuclear 
material which is released when the membrane breaks down. Cells were washed, trypsinized 
and centrifuged at 4°C, 350 x g for 10 min. After decanting the supernatants cells were 
resuspended in 1 ml ice cold 1x Nexin buffer, centrifuged again and resuspended in 1 ml 1x 
Nexin buffer. 5 µl Annexin V-PE and   5 µl Nexin 7-AAD were added to 40 µl of each cell 
suspension and incubated on ice for 20’ protected from light. Then 450 µl 1x Nexin buffer 
were added and the samples were measured using the GUAVA PCA.  
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4.9 Statistical analysis 
 
Statistical analysis to determine significance of all experiments was carried out using 
SigmaPlot and the unpaired t-test. Counting of statistical significance was always performed 
against the values of the corresponding negative control. The p-value is a probability with a 
value ranging from zero to one. In this work all p-values ≤ 0,05 were determined significant. 
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Results 
 
5. 15-LOX-1 expression in pancreatic cancer cells 
  
5.1 mRNA expression 
 
Preliminary data showing by IHC that 15-LOX-1 expression may be lost during pancreatic 
carcinogenesis. Western blotting revealed no or very weak expression of 15-LOX-1 in all 
pancreatic cancer cell lines tested compared to mononuclear cells (see discussion). 
To confirm these data, 15-LOX-1 mRNA expression was analyzed by RT-PCR in various 
human pancreatic cancer cell lines. As shown in Fig. 8a, 15-LOX-1 mRNA expression was 
below the level of detection in all cancer lines tested including MiaPaCa2, Panc-1, S2-O13, 
AsPC-1, Capan I, and Capan II. HEK293 cells transiently transfected with a 15-LOX-1 
expression plasmid were used as a positive control. As negative controls RNA from HEK293 
cells and water were used. The primers for 15-LOX-1 amplify a product of 340bp (Fig. 7a). 
Quality of the used cDNA was confirmed by actin PCR, amplifying a product of 234 bp (Fig. 
7b). 
 
a)             b)  
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Fig. 7: 15-LOX-1 expression in pancreatic cancer cell lines tested on mRNA level 
Total RNA was isolated from various human pancreatic cancer cell lines and from HEK293 cells transiently transfected with a 
15-LOX-1 expressing plasmid. RNA was reverse-transcribed to cDNA and PCR was run with specific primers for 15-LOX-1 (a) 
and human β-actin (b), as described in material and methods. Lane 1: positive control, lane 2: HEK293, lane 3: non-RT control, 
lane 4: MiaPaCa2, lane 5: Panc-1, lane 6: S2-O13, lane 7: AsPC-1, lane 8: Capan I, lane 9: Capan II, lane 10: H2O 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
5.2 Protein expression 
 
As no 15-LOX-1 expression could be detected on mRNA level, expression on protein level 
was analyzed for verification of the obtained results. Before screening pancreatic cancer cell 
lines and normal duct cells for 15-LOX-1 expression, anti-sera directed against individual 
LOX isoforms were analyzed with regard to their cross-reactivities with other members of the 
LOX family. The specificities of the used anti-sera could be ascertained clearly (Fig. 8). With 
one exception, the anti-sera exhibited mono-specificities for the respective LOX isoforms as 
shown  for 15-LOX-1, eLOX3, 5-LOX, 15-LOX-2 and 12R-LOX. Only the antiserum directed 
against p12-LOX showed cross reactivity with 15-LOX-2. 
1          2           3          4          5          6    7
70 kDa eLOX3
5-LOX79 kDa
p12-LOX70 kDa
12R-LOX70 kDa
15-LOX-270 kDa
15-LOX-170 kDa
 
Fig. 8: Cross reactivity screening of the different LOX antibodies 
Cross reactivity of the LOX antibodies was checked using western blot analysis. Cell homogenate protein (30 µg) from 
sonicated HEK293 cells transiently transfected with different LOX constructs were separated on a 10% SDS-PAGE, blotted onto 
nitrocellulose membrane and incubated with antibodies against the different LOX isoforms as indicated.  
Lane 1: negative control, lane 2: p12-LOX, lane 3: 5-LOX, lane 4: eLOX3, lane 5: 12R-LOX, lane 6: 15-LOX-2, lane 7:            
15-LOX-1. 
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Results 
 
Normal duct biopsies were taken from different patients who underwent pancreatic surgery. 
The ducts were placed onto collagen type I coated dishes and cultured for two weeks at 
37°C and 5% CO2. In Figure 9, epithelial cells grown out of the biopsies are shown. These 
epithelial cells were isolated and protein was extracted for western blot analysis.  
Fig. 9: Duct cells 
After 2 weeks of cultivation the out-grown cells were analyzed using a light microscope to verify fibroblast free cultures. No 
contamination was detectable in the selected sample.  
 
The isolated normal duct cells were first screened for the duct marker cytokeratin 19 (CK19) 
to verify the ductal origin. As positive controls two pancreatic ductal adenocarcinoma cell 
lines were used. As shown in Figure 10a the duct cells expressed CK19 in accordance with 
their ductal origin. Furthermore, 15-LOX-1 expression was detected in these freshly isolated 
normal duct cells (Fig. 10b). 
 
  a)            b) 
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Fig. 10: Western blot detection of 15-LOX-1 in normal duct cells 
30 µg total protein lysates from cells were separated on 10% SDS-PAGE and immunoblotting was performed using specific 
antibodies against (a) CK19 (1:1000), lane 1: MiaPaCa2, lane 2: S2-O13, lane 3: normal duct cells and (b) 15-LOX-1 (1:10000),  
lane 1: positive control, lane 2: normal duct cells. 
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Results 
 
After detection of 15-LOX-1 expression in normal duct cells, expression in pancreatic cancer 
cell lines was analyzed. On the protein level no 15-LOX-1 expression was detectable in all 
tested cell lines (Fig. 11). Thus, the lack of  15-LOX-1 expression on mRNA and protein level 
in all tested pancreatic cancer cell lines indicates that the expression of this LOX isoform is 
lost during pancreatic carcinogenesis. The normal bovine duct cell line AMA did not show 
any 15-LOX-1 expression, which might be due to non-reactivity with the antiserum. 
 
50 kDa
70 kDa
Tubulin
1       2       3       4 5     6        7        8       9
15-LOX-1
 
Fig. 11: 15-LOX-1 expression in pancreatic cancer cells 
30 µg total protein lysates from cells were separated on 10% SDS-PAGE and immunoblotting was performed using specific 
antibodies against 15-LOX-1 and γ-tubulin. Equal loading was determined by γ-tubulin expression. Lane 1: negative control,            
lane 2: Capan I, lane 3: Capan II, lane 4: AsPC-1, lane 5: Panc-1, lane 6: AMA, lane 7: S2-O13, lane 8: T3M4, lane 9: positive 
control. 
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5.3 Caffeic acid increases cell proliferation in normal duct cells 
affeic acid (CA) has been reported to be a selective inhibitor for 15-LOX-1 (see 
Fig. 12: 
seeded into 96 well plates. After 24 hours the medium was replaced 
 
 
 
C
introduction). Treatment of colon cancer cells with doses of 2.2 µM and 4.4 µM caffeic acid 
that inhibited 15-LOX-1 activity reversed the 15-LOX-1 induced growth inhibitory effect 
significantly. Therefore, it was checked if caffeic acid increased cell proliferation in primary 
duct epithelial cells that express 15-LOX-1 (see Fig. 10) at similar dose ranges. CA was 
indeed able to increase cell proliferation in a dose-dependent manner about 70% after 48 
hours (p<0.001) and about 80% after 72 hours (p<0.001) compared to untreated cells at a 
concentration of 10 µM. 4.4 µM caffeic acid showed a significant increase comparable to that 
of 10µM only after 72 hours (p<0.001), while 2,2 µM had no effect at all (Fig. 12). 
Ducts +/- CA
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CA treatment leads to increased cell proliferation 
WST-1 assay: 1000 cells/ 100 µl of normal duct cells were 
by medium supplemented with 2. 2µM, 4.4 µM, or 10 µM CA or the appropriate solvent. At the mentioned time points 10µl of the 
ready-to-use WST-1 reagent were added to the cells. After 1 hour incubation at 37°C and 5% CO2 proliferation was measured at 
450 nm using an ELISA reader. 
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Results 
 
6. Establishment of 15-LOX-1 over-expressing cells 
r cells, 15-LOX-1 over-
expressing cells were established. MiaPaCa2, S2-O13 and Panc-1 were transfected with     
 
 
Fig. 13: 15-L
30 µg total using specific 
ntibodies against 15-LOX-1 and β-actin. a) Clear expression was detected in MiaPaCa2-15-LOX-1 (cl 13) and S2-O13-15-
 control, lane 2: MiaPaCa2, lane 3: 
 
 
To investigate the function of 15-LOX-1 in human pancreatic cance
15-LOX-1 expressing constructs and all clones stably expressing 15-LOX-1 were selected.
Western blot analysis demonstrated high level of 15-LOX-1 expression in MiaPaCa2 clone 
13, S2-O13 clone 8 (Fig. 13 lane 3 and 5) compared to their Mock transfected clones. No 
over-expressing clone could be derived from Panc-1 cells (Fig. 13 lane 7). 
 
1       2       3       4     5       6   7
15-LOX-1
actin
70kDa
45kDa
OX-1 expression in 15-LOX-1 transfected cells compared to their Mock cells 
protein lysates from cells were separated on 10% SDS-PAGE and immunoblotting was performed 
a
LOX-1 (cl 8). b) Equal loading was determined by actin expression. Lane 1: positive
MiaPaCa-15-LOX-1 (cl 13), lane 4: S2-O13, lane 5: S2-O13-15-LOX-1 (cl 8), lane 6: Panc-1, lane 7: Panc-1-15-LOX-1 (cl 1). 
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Results 
 
6.1 15-LOX-1 enzyme activity in stably transfected MiaPaCa2 and S2-O13 cells 
 
o assure the activity of the transfected 15-LOX-1 cDNA the enzymatic activity of 15-LOX-1 
 cells 
upon incubation with arachidonic acid (AA). In both 15-LOX-1 expressing cell lines the 
ried under vacuum, re-dissolved in methanol-water-acetic acid (82:18:0.01, v:v), injected on a 5 µM YMC-Pack ODS-AM 
d at 235nm. The retention time of 15-S-HETE used as standard was 
0        2       4        6        8      10      12     14     16      18     20      22      24     26     28      30     32 34
T
was determination by 15-S-HETE formation in protein lysates of MiaPaCa2 and S2-O13
production of 15-S-HETE was detectable (Fig. 14a&b), while no 15-S-HETE production was 
observed in Mock transfected clones (Fig. 14c&d). 
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Fig. 14: Activity assay for 15-LOX-1 over-expressing cells 
RP-HPLC analysis of the products formed in cell extracts from stably transfected 15-LOX-1 expressing cell lines. Cell 
homogenates were incubated with 10 µM AA for 45 min and products were extracted with methanol-dichloromethane (1:1, v:v), 
d
column, and eluted at 0.5 ml/min. The eluate was monitore
24.5 min. After lipid extraction 15-S-HETE was detected in the 15-LOX-1-over-expressing cells (a&b) but not in the Mock 
transfected ones (c&d). This result could be confirmed for MiaPaCa2 and S2-O13. 
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.  Functional role of 15-LOX-1 expression7  
 
7.1 Effect of 15-LOX-1 on cell growth 
 
ells, the proliferation of 15-LOX-1 over-expressing 
inhibited , as measured by both WST-1 assay 
Fig. 15: 15-LOX-1 expression inhibits cell growth in MiaPaCa2 and S2-O13 
a&c WST-1 assay: 1000 cells/ 100 µl were seeded into 96 well plates. At the mentioned time points 10 µl of the ready-to-use 
reagent were added to the cells. After 1 hour incubation at 37°C and 5% CO2, proliferation was measured at 450 nm using an 
ELISA reader. Growth inhibition was significant at 96 and 120 hours in MiaPaCa2 (p<0.001 and p<0.001) and S2-O13 (p<0.001 
and p<0.001). b&d Cell counting: Cells were plated at a concentration of 25,000 cells/ ml with a final volume of 2 ml into 60 mm 
dishes. The number of living cells was counted at indicated time points using the GUAVA–PC. Growth inhibition was significant 
at 96 and 120 hours in MiaPaCa2 (p<0.001 and p<0.001) and S2-O13 (p<0.001 and p<0.0001). 
When compared with Mock transfected c
MiaPaCa2 and S2-O13 cells was significantly 
and cell counting. Highly significant differences in the cell numbers were observed at 96 and 
120 hours after seeding determined by the WST-1 assay (MiaPaCa2: ~55%; 20%; S2-O13: 
40%; 15%, respectively). Cell counting also revealed a significant decrease of the cell 
numbers after 96 hours up to 120 hours for recombinant MiaPaCa2  (~50%; 60%) and S2-
O13 cells (~30%; 40%). WST-1 results are shown in Figure 15a&c and cell counting results 
in Figure 15b&d. 
a)                                                                      b) 
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c)                d) 
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7.2 Effect of LOX products on cell growth 
 
7.2.1 Exogenous 15-S-HETE treatment 
 
15-LOX-1 has been shown to accept both AA and LA as substrates with comparable 
ls 
ST-1 assay: 1000 cells/ 100 µl of MiaPaCa2 and S2-O13 were seeded into 96well plates. After 24 hours the medium was 
replaced by serum-free medium supplemented with 1 µM 15-S-HETE. At the mentioned time points 10 µl of the ready-to-use 
reagent were added to the cells. After 1 hour incubation at 37°C and 5% CO2, proliferation was measured at 450 nm using an 
ELISA reader. GUAVA cell counting: cells were plated at a concentration of 25,000 cells/ ml with a final volume of 2 ml into      
60 mm dishes. After 24 hours the medium was replaced by serum-free medium supplemented with 1 µM 15-S-HETE. The 
number of living cells were counted at indicated time points using the GUAVA cell counter.  
 
 
**
efficiency. To examine whether 15-LOX-1 mediated growth inhibition was due to the LOX 
products the effects of exogenous treatment with 15-S-HETE and 13-S-HODE on cell growth 
were analyzed. MiaPaCa2 and S2-O13 cell lines were exogenously treated with its AA 
derived product 15-S-HETE. While, 24 hours after treatment of MiaPaCa2 no significant 
decrease in proliferation was detected for MiaPaCa2 (p=0,449) determined by WST-1 and 
cell counting (p=0,168), at 96 hours time point a significant decrease in proliferation of ~40% 
was measurable for MiaPaCa2 (Fig. 16a) determined by WST-1. Similar effect was 
determined by cell counting, though measured decrease was only about 20%. (p<0,008 and 
p<0,001). Same effect was observed in S2-O13 (Fig. 16b) exhibiting a decreased 
proliferation ~20 -30% determined by WST-1 and cell counting (p<0,02 and p<0,001).  
a) 
MiaPaC2 +/- 15-S-HETE
MiaPaCa2 +/- 15-S-HETE
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b) 
Fig 16: Effect of exogenous 15-S-HETE (1 µM) on proliferation of MiaPaCa2 and S2-O13 cel
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7.2.2 Exogenouse 13-S-HODE treatment  
 
15-LOX-1 is known to metabolize AA but also LA to form 13-S-HODE. 
with 13-S-HODE. The 
in S2-O13 (Fig. 17b) cells at 24 hours past treatment 
                
Fig
-1 assay: 1000 cells/ 100 µl of MiaPaCa2 (a) and S2-O13 (b) were seeded into 96 well plates. After 24 hours the medium 
replaced by serum-free medium supplemented with 1 µM 13-S-HODE. At the mentioned time points 10 µl of the ready-to-
ured at 450 nm using 
Parental MiaPaCa2 and S2-O13 cell lines were exogenously treated 
incubation with 1 µM of this metabolite had no significant effect on proliferation in both cell 
lines. For MiaPaCa2, 24 hours after treatment a slight decrease in proliferation (~ 25%) was 
detected (MiaPaCa2: p=0.002) determined by WST-1 however, this effect could not be 
verified by cell counting (p=0.424). In addition, 96 hours after treatment no significant 
decrease in proliferation was measurable for MiaPaCa2 (Fig. 17a) using WST-1 and cell 
counting (p=0.365 and p=0.279). 
The same effect was observed 
(p=0.852 and p=0.424) analyzed by WST-1 and cell counting. Even after 96 hours no effect 
was measurable determined by WST-1 and cell counting (p=0.436 and p=0.279).  
WST-1 (right graphs) and cell counting (left graphs).  
a) 
MiaPaCa2 +/- 13-S-HODE MiaPaCa2 +/- 13-S-HODE
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b) 
. 17: Effect of exogenous 13-S-HODE (1µM) treatment on proliferation of MiaPaCa2 and S2-O13 cells 
WST
was 
use reagent were added to the cells. After 1 hour incubation at 37°C and 5% CO , proliferation was meas2
an ELISA reader. Cell counting with GUAVA-PC: cells were plated at a concentration of 25,000 cells/ ml with a final volume of   
2 ml into 60 mm dishes. After 24 hours the medium was replaced by serum-free medium supplemented with 1 µM 13-S-HODE. 
The number of living cells were counted at indicated time points using the GUAVA cell counter.  
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7.3 Stimulation of growth inhibition by 15-LOX-1 substrates 
 
7.3.1 Exogenous AA inhibits cell growth 
 
The AA iferation inhibitory activity. Treatment with 
A was performed to examine if the same effect could be achieved or if the growth inhibitory 
b) 
Fig. 18: Effect  Mock transfected 
and 15-LOX-1 
 derived product 15-S-HETE revealed a prol
A
effect could still be enhanced. After 24 hours treatment no significant effect of exogenous AA 
on growth was observed in Mock and 15-LOX-1 cells. After 120 hours, however, 15-LOX-1 
over-expressing cells showed a decreased proliferation of about 60% as determined by 
WST-1 (p<0.001). In Mock cells, proliferation decreased about 25% (p=0.015). Similarly, a 
decreased proliferation (~ 30%) was detected in S2-O13-15-LOX-1 over-expressing cells, 
120 hours after exogenous AA treatment (p=0.007). In contrast, no effect on growth was 
observed in Mock transfected cells (Fig. 18). 
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 of 5 µM exogenous arachidonic acid  on proliferation of treatment for MiaPaCa2 and S2-O13
over-expressing cells. WST-1 assay: carried out as described under Fig. 15. 
2.0
Mock + AA 5 µM
24 120
0.0
0.5
1.0
1.5
Mock + solvent
15-LOX-1 + AA 5 µM
15-LOX-1 + solvent
time in hours
ab
so
rb
an
ce
 [4
50
nm
]
*
ab
so
rb
an
ce
 [4
50
nm
]
 
 
Results 
 
7.3.2 Treatment with the 15-LOX-1 substrate linoleic acid  
 
Treatment of MiaPaCa2 with LA did not show any inhibition in cell proliferation in Mock and 
b) 
Fig. 19: P  cells 
WST-1 assay: the medium was 
ced by serum-free medium supplemented with 5 µM LA. At the mentioned time points 10 µl of the ready-to-use reagent 
ELISA 
15-LOX-1 transfected cells. Proliferation was measured at two different time points after 
treatment with 5 µM LA. No significant decrease was observed. Even after 24 hours and 120 
hours of treatment (Fig.19a). These results were confirmed for recombinant S2-O13 cells 
(Fig. 19b). 
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roliferation analysis after 5 µM exogenous linoleic acid treatment for MiaPaCa2 and S2-O13 transfected
1000 cells/ 100 µl of MiaPaCa2 or S2-O13 were seeded into 96 well plates. After 24 hours 
repla
were added to the cells. After 1 hour incubation at 37°C and 5% CO2, proliferation was measured at 450 nm using an 
reader. 
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. LOX inhibitors reduce cell proliferation8  
 
8.1 Effect of NDGA on cell growth 
 
The previous results indicate that 15-LOX-1 and its AA-derived product 15-S-HETE inhibit 
rowth of pancreatic cancer cells. Studies using the general LOX inhibitor NDGA and the 
b) 
Fig. 20: Effect of LOX inhibitor NDGA on cell growth in MiaPaCa2 and S2-O13 
GUAVA cell counting: cells were plated at a concentration of 25,000 cells/ ml with a final volume of 2 ml into 60 mm dishes. 
After 24 hours the medium was replaced by serum-free medium supplemented with 10 µM NDGA. Cell counting was carried out 
at the indicated time points. 
 
g
more specific LOX inhibitor baicalein were performed to evaluate if inhibition of LOX activity 
may reverse the 15-LOX-1 induced growth inhibition. At 24 hours decrease in Mock cells was 
about 40% and in 15-LOX-1 transfected cells about 75% in proliferation (Fig. 20a) using cell 
counting (p<0.001 and p=0.001, respectively). Inhibition of cell growth in 15-LOX-1 cells was 
about 90% (p<0.001). Similar, significant decrease (~90%) was observed after 120 hours in 
Mock cells (p<0.001).  
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8.2 Baicalein inhibits cell proliferation 
ikewise, treatment of MiaPaCa2 with baicalein resulted in the inhibition of cell growth. 
b) 
Fig. 21: Eff
final volume of 2 ml into 60 mm dishes. 
 
L
Proliferation of Mock cells was decreased by about 90% (p<0.002) and that of 15-LOX-1 
cells by about 60% (p=0.007) after 24 hours. At 120 hours after treatment, proliferation of 
Mock cells and 15-LOX-1 cells was suppressed by about 80% (p<0.001) and 60%, 
(p<0.001), respectively (Fig. 21a). Treatment of S2-O13 with baicalein also resulted in a 
strong inhibition of cell growth (Fig. 21b). 
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ect of LOX inhibitor baicalein on cell growth in MiaPaCa2 and S2-O13 cells 
GUAVA cell counting: cells were plated at a concentration of 25,000 cells/ ml with a 
After 24 hours the medium was replaced by serum-free medium supplemented with 10 µM baicalein. The number of living cells 
were counted at indicated time points using the GUAVA-PC. 
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9. Mechanisms involved in 15-LOX-1-mediated growth inhibition 
.1 Effect of 15-LOX-1 expression on cell cycle
 
9  
As in Fig. 23 over-expression of 15-LOX-1 led to decreased proliferation as compared 
                  
m w
) 
 
) 
 
Fig. 22: 
hours after seeding cells were prepared as described in material 
 
shown 
to Mock transfected cells. To investigate the molecular mechanism involved in  
15-LOX-1 ediated gro th inhibition cell cycle analysis were carried out. As shown in Figure 
22 a&b no difference in cell cycle progression could be observed in 15-LOX-1 over-
expressing MiaPaCa2 and S2-O13 cells as compared to control cells. 
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Cell cycle analysis for 15-LOX-1 over-expressing cells 
Cell cycle analysis was carried out using FACS analysis. 120 
and methods. As shown for both cell lines a) MiaPaCa2 and b) S2-O13 no difference in cell cycle progression could be 
detected. 
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.2 Increased apoptosis in 15-LOX-1 over-expressing cells9  
As o difference in cell cycle progression was detected in 15-LOX-1 over-expressing cells  
b)  
methods. The assay was performed with cells grown for 120 hours. Cells were trypsinised washed and stained with 7-AAD and 
Annexin V. After 20 min incubation cells were measured using the GUAVA-PC. 15-LOX-1 expressing cells were compared to 
Mock cells. In a) MiaPaCa2 and b) S2-O13 significant increase of apoptosis could be observed in 15-LOX-1 transfected cells 
(p<0.001 and p<0.001). 
 
 
 
 
 
n
compared to Mock cells, the rate of apoptosis was determined (Fig. 23a). The comparison of 
MiaPaCa2-15-LOX-1 with MiaPaCa2-Mock cells showed an increase of apoptosis up to 
~25% at 120 hours after seeding. In S2-O13 cells the rate of apoptosis was only marginally 
increased by about 8% (Fig. 23b).  
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Fig. 23: Determination of apoptosis in 15-LOX-1 over-expressing cells 
Apoptosis was measured using the GUAVA Nexin assay according to manufacturers protocol described in material and 
0
5
10
15
20
25
30
35
Mock
15-LOX-1
120 hours
ap
*
op
to
tic
 c
el
ls
 [%
]]
ap
op
to
tic
 c
el
ls
 [%
Results 
 
 - 61 – 
 
 
is of signaling pathway potentially involved in 15-LOX-1 mediated growth 9.3 Analys
inhibition 
 
9.3.1 Genestein 
as 
determined by WST-1 (p=0.006) and cell counting (p=0.004) at 120 hours after treatment. 
a) 
Fig. 24: P
a) 5.  
 
 
To delineate potential signaling cascades involved in 15-LOX-1 effected growth inhibition in 
pancreatic cancer cells, pharmacologic kinase inhibitors were used. In a first set of 
experiments 15-LOX-1 over-expressing cells and Mock control cells were incubated in 
medium containing 10 µM genestein, a specific tyrosine kinase inhibitor (Fig. 24a&b). While 
no effect on growth was observed in Mock cells. A clear reversion of 15-LOX-1-induced 
growth inhibition was observed in 15-LOX-1 over-expressing MiaPaca2 and S2-O13 cells 
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 WST-1 assay: carried out as described under Fig. 15 b) GUAVA cell counting: carried out as described under Fig. 1
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Likewise, S2-O13-15-LOX-1 cells and Mock cells were treated with 10 µM genestein. 
Proliferation was measured at two different time points using WST-1 (Fig. 25a) and cell 
nting (Fig. 25b). In Mock cells, cell growth after 24 hours and 120 hours (p=0.241 and 
.099) was not affected. In S2-O13-15-LOX-1 cells the 15-LOX-1 induced growth inhibition 
as observed at 120 hours 
b) 
2, proliferation was measured at 450 nm using an ELISA reader. 
b) GUAVA cell counting: cells were plated at a concentration of 25,000 cells/ ml with a final volume of 2 ml into 60 mm dishes. 
After 24 hours the medium was replaced by medium supplemented with 10 µM genestein. The number of living cells were 
counted at indicated time points using the GUAVA cell counter. 
  
 
 
 
cou
p=0
was not reversed at 24 hours However, a clear reversion (~30%) w
after treatment (WST, p=0.006; cell counting, p=0.004). 
a) 
S2-O13 +/- Genestein
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Fig. 25: Proliferation analysis for S2-O13 after treatment with the MAPK inhibitor genestein 
a) WST-1 assay: 1000 cells/ 100 µl of S2-O13 were seeded into 96 well plates. After 24 hours the medium was replaced by 
medium supplemented with 10 µM genestein. At the mentioned time points 10 µl of the ready-to-use reagent were added to the 
cells. After 1 hour incubation at 37°C and 5% CO
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9.3.2 Effect of MEK1/2 inhibitor on cell proliferation 
 
Next, using 
specifi these 
inhibitors rowth 
cells 
 
g. 26: Proliferation analysis for MiaPaCa2 after treatment with the MAPK inhibitor MEK1/2 
ST-1 assay: 1000 cells/ 100 µl of MiaPaCa2 were seeded into 96well plates. After 24 hours the medium was replaced by 
edium supplemented with either 10 µM MEK1/2 inhibitor or solvent. At the mentioned time points 10 µl of the ready-to-use 
agent were added to the cells. After 1 hour incubation at 37°C and 5% CO2, proliferation was measured at 450 nm using an 
LISA reader. 
 
 
the Mitogen-activated kinases (MAPK) signaling pathway was addressed by 
c inhibitors for MEK1/2 and ERK. Treatment of transfected MiaPaCa2 cells with 
did not reverse the LOX-induced growth inhibition but in contrast induced g
suppression by itself. Suppression of growth in 15-LOX-1 over-expressing MiaPaCa2 
was about 20% (p=0.02; Fig. 26).  
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9.3.3 Effect of PD98 on cell proliferation 
 
Similarly, treatment of MiaPaCa2-Mock and MiaPaCa2-15-LOX-1 with the ERK inhibitor 
PD98 10%) cells 
after 24 hours of 
incubation and even 
stronger after 129 
 
g. 27: Proliferation analysis for S2-O13 after treatment with the MAPK inhibitor PD98 
ST-1 assay: 1000 cells/ 100 µl of MiaPaCa2 were seeded into 96 well plates. After 24 hours the medium was replaced by 
supplemented with 50 µM PD98 or solvent. At the mentioned time points 10 µl of the ready-to-use reagent were added 
 the cells. After 1 hour incubation at 37°C and 5% CO2, proliferation was measured at 450 nm using an ELISA reader. 
 
 
showed only a minor decrease in Mock (~20%) as well as in 15-LOX-1 (~
hours (MiaPaCa2-Mock p<0.001; MiaPaCa2-15-LOX p=0.009). After 120 
the inhibitory effect of PD98 increased in 15-LOX-1 cells (~20%) 
in Mock cells (~40%). The observed inhibition (Fig. 27) of cell growth 
hours was statistically significant for 15-LOX-1 (p<0.001) and Mock cells (p=0.009). 
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10. HDAC inhibitors 
 
10.1 Effect of different HDAC inhibitors on pancreatic tumor cell proliferation 
 
It is known that HDAC inhibitors inhibit cell proliferation in several cancer cell lines (e.g. lung 
cancer and pancreatic cancer cells) via induction of apoptosis (see introduction). Additionally, 
it has been described that HDAC inhibitors do restore 15-LOX-1 expression human colon 
cancer cells (see introduction). MiaPaCa2 and S2-O13 cell lines were treated with the HDAC 
inhibitors sodium butyrate (NaBu), SAHA, and Trichostatin A (TA) to prove that the inhibitory 
           
 WST-1 assay: carried out as described under Fig. 15.  
effect could also be observed in these pancreatic cancer cell lines. Already after 24 hours of 
treatment MiaPaCa2 (Fig. 28) showed a strong decrease in cell proliferation, which lasted up 
to 120 hours, when treated with 5mM NaBu (~ 70%), 2.5 µM SAHA (~ 100%), and TA
(~ 100%). Similar observations were made for S2-O13. 
Fig
a)
. 28: Proliferation analysis after NaBu treatment for MiaPaCa2 and S2-O13 
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11. NaBu alters metastatic protein expression 
 
11.1 NaBu restores expression of the anti-metastatic protein KAI1 
 
Previously, it has been described that NaBu not only induces apoptosis but also restores the 
expression of KAI1, an anti-metastatic protein n prostate cancer cells (see introduction). To 
date no such findings were made in pancreatic cancer cells (see introduction). First, several 
pancreatic cancer 
i
cells were screened for KAI1 expression. As shown in Figure 29a, three 
I, Panc-1, and T3M4) out of six tested cell lines expressed the anti-metastatic protein 
were used as positive controls in the subsequent induction experiments with the KAI1 
negative a slight 
induction 24 and 48 
hours (Fig. 
a) 
b)  
estern blot analysis was carried out for MiaPaCa2. Cells were seeded and 24 hours later treated with 5 mM NaBu. Protein 
sates were prepared after different incubation times. 30 µg lysates were analyzed using 10% SDS-PAGE and immunoblotted 
nto nitrocellulose membrane. After incubation with the specific KAI1 antibody (1:1000) KAI expression in different pancreatic 
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(Capan 
and 
cell lines MiaPaCa2 and S2-O13. In MiaPaCa2, six hours after treatment 
of KAI1 protein expression was detectable which became stronger after 
29b).  
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Fig. 29a&b: KAI1 induction after NaBu treatment in MiaPaCa2 
W
ly
o
cancer cell lines was detected (a). Lane 1: AsPC-1, lane 2: Capan I, lane 3: Capan II, lane 4: Panc-1, lane 5: S2-O13, lane 6: 
T3M4. b) Clear KAI1 expression could be detected after 6 hours up to 48 hours. Equal loading was verified by β-actin (1:5000). 
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Results 
 
In S2-O13 cells, KAI1 expression started about one hour after treatment with NaBu and 
increased wi 29c).  
c) 
detected after 24 hours. No signal could be detected after 48 hours. Equal loading was verified by β-actin (1:5000). 
th time. After 48 hours the intensity of KAI1 expression decreased (Fig. 
KAI 1
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Fig. 29c: KAI1 induction after NaBu treatment in S2-O13 
Western blot analysis was carried out for S2-O13. Cells were seeded and 24 hours later treated with 5 mM NaBu. Protein 
lysates were prepared after different incubation times. 30 µg lysates were analyzed using 10% SDS-PAGE and immunoblotted 
onto nitrocellulose membrane. After incubation with the specific KAI1 antibody (1:1000) slight KAI1 expression could be 
1 hour up to 
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11.2 NaBu has no effect on the pro-metastatic protein S100A4 
. Figure 32 documents that NaBu has no effect on the expression of 
S100A4 in MiaPaCa2. 
a) 
b) 
g. 30b: S100A4 expression S2-O13 
t for S2-O13. Cells were seeded and 24 hours later treated with 5 mM NaBu. Protein 
 
On the other hand, the pro-metastatic protein S100A4 was reported to be expressed in 
pancreatic tumor cell lines (see introduction). This was found to be true also for MiaPaCa2 
and S2-O13 cells (Fig. 30a&b). Western blot analysis was carried out to analyze whether or 
not NaBu can downregulate S100A4 expression concomitant with up-regulation of the anti-
metastatic protein KAI1
10kDa S100A4
actin45kDa
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Fig. 30a: S100A4 expression MiaPaCa2 
Western blot analysis was carried out for MiaPaCa2. Cells were seeded and 24 hours later treated with 5 mM NaBu. Protein 
lysates were prepared after different incubation times. 30 µg lysates were analyzed using 10% SDS-PAGE and immunoblotted 
onto nitrocellulose membrane. After incubation with the specific S100A4 antibody (1:1000) no altered expression could be 
detected. Equal loading was verified by β-actin (1:5000). 
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Western blot analysis was carried ou
lysates were prepared after different incubation times. 30 µg lysates were analyzed using 10% SDS-PAGE and immunoblotted 
onto nitrocellulose membrane. After incubation with the specific S100A4 antibody (1:1000) no altered expression could be 
detected. Equal loading was verified by β-actin (1:5000). 
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12. Restoration of 15-LOX-1 expression by NaBu 
s shown in Fig. 28, growth of pancreatic tumor cells can be inhibited by different HDAC 
 ancer rectal                
ction). o in cell
Fig. 31a: 
Western blot Bu. Protein 
tes were prepared after different incubation times. Cell homogenate proteins (30µg) from sonicated MiaPaCa2 cells treated 
 onto nitrocellulose membrane and incubated with antibodies 
observed up to 48 hours after treatment. In general, the induction of 15-LOX-1 expression 
Fig. 31b: 
Western blot ana
 
 
A
inhibitors and NaBu does also influence the expression of the anti-metastatic protein KAI1. 
Moreover, HDAC inhibitors such as NaBu were shown to be able to restore 15-LOX-1 
expression in different c  cells, including colo and lung cancer cells    
(see introdu To prove if this bservation can also be made pancreatic cancer s,   
MiaPaCa2 cells (Fig. 31a) and S2-O13 cells (Fig. 31b) were treated with the HDAC inhibitor 
NaBu. In MiaPaCa2 cells, NaBu could indeed induce the expression of 15-LOX-1, which 
could be detected after 6 hours of induction and steadily increased up to 48 hours.  
a) 
15-LOX-1
actin
70kDa
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0‘      5‘      30‘      1h      6h      24h      48h      PC  
15-LOX-1 induction in MiaPaCa2 after NaBu treatment 
analysis was carried out for MiaPaCa2. Cells were seeded and 24 hours later treated with 5mM Na
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lysa
with 5mM NaBu were separated on a 10% SDS-PAGE, blotted
against 15-LOX-1 (1:10000) and β-actin (1:5000). Clear signal could be seen for 15-LOX-1 6 hours after incubation remaining 
stable up to 48 hours. Equal loading was verified by β-actin.  
 
In S2-O13 cells 15-LOX-1 expression was already induced after 30 min and could be 
was not as strong as in MiaPaCa2, but occurred  earlier. 
b) 
15-LOX-1
actin
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45kDa
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15-LOX-1 induction in S2-O13 after NaBu treatment 
lysis was carried as described under Fig. 31a. 
 
 
 
Results 
 
12.1 Caffeic acid does not reverse the growth inhibitory effects of NaBu and SAHA  
 order to study, whether the NaBu-induced inhibition of growth (Fig. 28) was causally 
h 
e 15-LOX-1 inhibitor CA. As shown in Figure 32 the inhibitory effect of 5 mM NaBu could 
b) 
Fig. 32: P
WST-1 assay: the medium 
was replaced ntioned time 
points 10 µl proliferation was 
sured at 450 nm using an ELISA reader. 
 
 
In
related with the induction of 15-LOX-1, NaBu-treated cells were treated simultaneously wit
th
not be reversed by inhibition of the 15-LOX-1 activity with 10 µM CA in both, MiaPaCa2 cells 
(Fig. 32a) and S2-O13 cells (Fig. 32b). No significant increase in cell proliferation was 
detectable for MiaPaCa2 (p=0,242 and p=0.585) and S2-O13 (p=0.842 and p=0.711) 
measured 24 and 120 hours after induction. 
a) 
MiaPaCa2 +/- NaBu/ CA
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1000 cells/ 100 µl of MiaPaCa2 and S2-O13 cells were seeded into 96 well plates. After 24 hours 
by medium supplemented with 5 mM NaBu and 10 µM CA or the appropriate solvent. At the me
of the ready-to-use reagent were added to the cells. After 1 hour incubation at 37°C and 5% CO2, 
mea
 
24 120
0.00
0.75
1.50
2.25
NaBu 5 mM*
*
NaBu 5 mM + CA 10 µM
H2O
H2O + EtOH
time in hours
ab
so
rb
an
ce
 [4
50
nm
]
ab
so
rb
an
ce
 [4
50
nm
]
S2-O13 +/- NaBu/ CA
24 120
0.00
0.75
1.50
2.25
NaBu 5 mM
NaBu 5 mM + CA 10 µM
H2O
H2O + EtOH
time in hours
ab
so
rb
an
ce
 [4
50
nm
]
* *
ab
so
rb
an
ce
 [4
50
nm
]
 
 
Results 
 
 - 71 – 
 
 
ion could not be overcome by 
 p=0.579). The same result was observed for S2-O13 after 
4 hours (p=0.582). After 120 hours, however, a significant increase of proliferation was 
b) 
g. 33: Proliferation assay for MiaPaCa2 and S2-O13 after SAHA and CA treatment 
ST-1 assay: 1000 cells/ 100 µl of MiaPaCa2 and S2-O13 cells were seeded into 96 well plates. After 24 hours the medium 
was replaced by medium supplemented with 2.5 µM SAHA and 10 µM CA or the appropriate solvent. At the mentioned time 
points 10 µl of the ready-to-use reagent were added to the cells. After 1 hour incubation at 37°C and 5% CO2, proliferation was 
measured at 450 nm using an ELISA reader. 
 
 
Likewise, SAHA (2.5 µM) effected inhibition of cell proliferat
treatment with the 15-LOX-1 inhibitor CA at any time point in both, MiaPaCa2 cells (Fig. 33a) 
and S2-O13 cells (Fig. 33b). No significant effect could be determined after 24 and 120 hours 
for MiaPaCa2 cells (p=0.717 and
2
measured in S2-O13 cells (p=0.001).  
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13. Discussion 
 
At present, there is no effective therapy for pancreatic cancer patients. Therefore,  prevention 
or early detection before this cancer has become invasive is thought to be an alternative 
strategy to cope with this situation. Even small resectable tumors recur or have metastasized 
in most cases within 2 years after primary surgery. Chemotherapy only prolongs life by a 
matter of weeks, maintaining the unchanged abysmal prognosis of pancreatic cancer. 
The development of pancreatic cancer is known to be closely associated with inflammatory 
processes. The observation of a connection between inflammation and cancer in general 
goes back to Virchow in 1863, when he noted a “lymphoreticular infiltrate” in neoplastic 
tissues [223]. He suggested the origin of cancer in the context of chronic inflammation. 
Inflammatory cells and cytokines more likely contribute to tumor growth and progression than 
to mount the host anti-tumor response [223]. In addition, pancreatic cancer is characterized 
by a strong desmoplastic reaction and in 1986 Dvorak pointed out that wound healing and 
tumor stroma formation share many important properties. He suggested that tumors are 
wounds that do not heal [223]. At the same time observations were made, showing that 
intake of NSAIDs not only reduces inflammation and pain but also decreases the risk of 
cancer [224], in particular colon cancer [223]. Therefore, the eicosanoid pathway that is 
targeted by NSAIDs seems to play an important role in tumor development, growth and 
progression. The eicosanoid pathway can be divided into the cyclooxygenase (COX), the 
P450, and lipoxygenase (LOX) pathway. Cyclooxygenases (COX) are the rate-limiting 
enzymes in prostaglandin synthesis and it is well accepted that the inducible isoform COX-2 
plays an important role in carcinogenesis [225]. Similarly, LOXs are reported to play an 
important role during tumourigenesis of different organ sites. Six human LOXs are 
characterized to date. Among the enzymes that are expressed in PanINs and pancreatic 
adenocarcinomas are 5-LOX and COX-2. Recently, 5-LOX has been suggested to be a 
tumor promoter in pancreatic carcinogenesis [226, 227]. Different studies using reverse 
transcriptase-polymerase chain reaction (RT-PCR) revealed expression of 5-LOX and 12-
LOX mRNA in all commonly used pancreatic cancer cell lines, including Panc-1, AsPC-1 and 
MiaPaCa2, but not in normal pancreatic ductal cells [228]. Similar results were obtained on 
protein level [227]. 5-LOX up-regulation in human pancreatic tissues was verified by 
immunohistochemistry, which resulted in intense positive staining in cancer cells and 
premalignant lesions [227]. 
There is also RT-PCR evidence for 12-LOX mRNA expression in pancreatic cancer cell lines 
[228]. Anderson et al. showed that pancreatic cancer cell proliferation was inhibited by 
treatment with MK886, which is known to antagonize the sequestration of arachidonic acid by 
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the 5-LOX activating protein (FLAP) thereby suppressing 5-LOX activity [219, 227-235]. Ding 
et al. described that a LOX inhibitor, that was extracted from the sea cucumber attenuates 
pancreatic cancer development [236]. 
The activities of 5-LOX and 12-LOX are obviously associated with pro-tumorigenic effects on 
different tumor cells. On the other hand the role of 15-LOX-1 has been discussed 
controversially [236]. Expression of 15-LOX-1 has been associated with anti-tumorigenic 
effects in the colon but pro-tumorigenic effects in the prostate, indicating tissue selectivity for 
this LOX [221, 237]. In the pancreas, Hennig et al. showed that 15-LOX-1 protein was 
expressed in normal prancreatic tissue showing up as strong granular cytoplasmic staining in 
normal duct cells, pseudoducts, and centroacinar cells while no staining was seen in islets 
when analyzed immunohistochemically. Cancer cells or cells of PanIN lesions did not 
express 15-LOX-1. In addition, no or very weak expression of 15-LOX-1 was reported for 
pancreatic cancer cell lines tested in this report as compared to 15-LOX-1-positive 
mononuclear cells [238]. 
As nothing is known about the role of 15-LOX-1 in pancreatic carcinogenesis its potential 
involvement in pancreatic carcinogenesis was object of this study. 
 
13.1 Expression of 15-LOX-1 mRNA and protein in pancreatic cancer cell lines 
 
The first step was to determine the mRNA and protein levels of 15-LOX-1 in several cancer 
cell lines from primary prancreatic tumors (Capan II, MiaPaCa-2, Panc-1), malignant ascites 
(AsPC-1), and liver metastases (S2-O13, Capan I). In fact, pancreatic cancer is known to 
metastasize in local lymph nodes, liver, peritoneum, adrenal glands, lung, kidney, spleen and 
bone [2, 109]. Therefore, S2-O13 and Capan I were used to investigate whether or not 
metastatic and primary tumor cell lines differ in their 15-LOX-1 expression pattern.  
On mRNA and protein level, no expression of 15-LOX-1 mRNA and protein was detectable in 
any of the tested cell lines which is in agreement with the loss of 15-LOX-1 expression in 
pancreatic cancer tissue [238]. In contrast, primary normal pancreatic ducts expressed          
15-LOX-1 protein thereby recapitulating the in vivo situation [239]. Similar observations were 
reported by Shureiqi et al. which showed the expression of 15-LOX-1 in normal colonic 
epithelial cells but not colon carcinoma cell lines [240]. 
These results led us to the conclusion that 15-LOX-1 expression is lost during pancreatic 
carcinogenesis pointing to an anti-tumorigenic rather than a pro-tumorigenic function of this 
LOX isozyme in pancreatic carcinogenesis.  
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13.2 The functional role of 15-LOX-1 
 
To analyze the role of 15-LOX-1 for pancreatic carcinogenesis, different 15-LOX-1 over-
expressing cell lines were established. Comparing to mock transfected cells a clear inhibition 
of proliferation was detectable in two 15-LOX-1 over-expressing cell lines. Similar 
observations have been already reported for cancer cells of the colon [241], esophagus 
[166], stomach [242], and prostate [180, 243].  
Further experiments were carried out to examine which of the two 15-LOX-1 metabolites, 15-
S-HETE or 13-S-HODE, mediated the observed decrease of proliferation in pancreatic 
cancer cells. Exogenous treatment with 1 µM 15-S-HETE led to decreased proliferation.  
Chen et al. showed a similar inhibitory effect of 15-S-HETE in colorectal cancer cells, though 
the concentrations used in this study ranked between 30 µM and 100 µM [244]. Likewise, Hsi 
et al. demonstrated a decreased proliferation in colorectal cancer cells that were treated with  
15-S-HETE in the dose range of 0.1 µM to 50 µM [245]. In contrast, 13-S-HODE did not 
show any altered proliferation in our pancreatic cancer cell lines at 1 µM concentration. 
Similar results were described by Shureiqi et al. in colon cancer cells, but they observed a 
decreased proliferation at higher concentrations of 13-S-HODE (50 µm up to 150 µM) [240]. 
In contrast, Hsi et al. showed a proliferation stimulating effect of 13-S-HODE in colon cancer 
cells when used at concentrations of 0.1 µM, 1 µM and 5 µM. An inhibitory effect was shown 
for higher concentrations (10 µM and 50 µM). These data suggest that the effect of              
13-S-HODE on the proliferation of colon cancer cells depends on the dose of this agent 
[240].  
The question then is which mechanisms are involved in the growth inhibitory activity of      
15-S-HETE in pancreatic cancer cell lines. In colon cancer cells, 15-S-HETE was found to 
activate PPARγ. This pathway finally leads to increased apoptosis in colon cancer cells. 
Whether or not this pathway is also true for pancreatic cells remains to be established. 
Interestingly, Shureiqi et al. showed that the pro-apoptotic effect of 13-S-HODE in colon 
cancer cells was associated with the down-regulation of PPARδ [241]. This effect could only 
be observed at low concentrations of 13-S-HODE that were not used in the study with 
pancreatic cancer cell lines.  
Incubating the 15-LOX-1 over-expressing cells with 5 µM AA also reduced proliferation 
significantly. As AA is converted to 15-S-HETE the inhibitory effect might be due to            
15-S-HETE accumulation and thereby the subsequent of downstream pathways. 
Furthermore, Monjezeb et al. showed that exogenous AA per se and inhibitors of AA 
metabolism that lead to the cellular accumulation of free AA were cytotoxic to the colon 
cancer cell line, HCT-116 [246]. Additionally, exogenous AA and triacsin C, an inhibitor of AA 
acylation, induced apoptosis via caspase-3 activation in a transcription-dependent manner. 
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Gene array analysis revealed that both exogenous AA and triacsin C alter the expression of 
similar genes in HCT-116 cells. For example, both down-regulate several genes with well-
documented roles in cell survival and apoptotic resistance [246]. Thus, AA-induced inhitibion 
of cell proliferation in 15-LOX-1 over-expressing cells can occur through pathways that are 
dependent or independent of LOX activity. Treatment with 5 µM AA did not show any 
difference in mock cells. A potential inhibitory activity of AA could be compensated by COX-
2-dependent synthesis of PGE2 which has been shown to stimulate proliferation through 
stimulation of growth-related genes and proliferation via PI3K signaling and NF- B 
translocation to the nucleus [247]. LA can also be metabolised by 15-LOX-1 and was 
therefore analysed as well. LA (1 µM) showed no effect. This result is conceivable with the 
observation that 13-S-HODE in the concentration used in my experiments does not inhibit 
cell growth in the pancreatic cell lines that were investigated.  
Causes for decreased cell proliferation may either be settled in modified cell cycle 
progression and/ or increased rate of apoptosis. Kim et al. reported that over-expression of 
15-LOX-1 induces growth arrest through phosphorylation of p53 in human colorectal cancer 
cells [221]. However, in my study no altered cell cycle progression was observed for 15-LOX-
1 over-expressing cells. On the other hand, LOX products have been shown to induce 
programmed cell death (PCD) in human T-cells [187], neutrophils [188], PC12h cells [189], 
and Jurkat cells [190]. Several other studies have shown the pro-apoptotic activity of 5-LOX      
[191, 192], of leukocyte type 12-LOX [193, 194], and of 15-LOX-1 [178, 195] and have 
identified molecular targets for LOX-mediated induction of apoptosis. However, also anti-
apoptotic effects of LOXs have been reported, mainly based on the observation that LOX 
inhibitors, most often nordihydroguaiaretic acid (NDGA) and MK886, exhibited pro-apoptotic 
activity [46, 196-198]. Interestingly, in other cellular types NDGA or MK886 protected against 
apoptosis [191, 194, 195, 199-202], or induced PCD in cell types completely devoid of LOX 
activity [203-205]. In this context, it should be recalled that most LOX inhibitors used in PCD 
studies, including NDGA, act by reducing the active Fe3+ enzyme to the inactive Fe2+ form. 
NDGA also blocks voltage activated calcium currents, inhibits P450 monooxygenase activity 
and acts as a general radical scavenger [201]. On the other hand, MK886, which inhibits 5-
LOX by blocking substrate sequestration through interaction with the 5-LOX activating 
protein (FLAP), can also induce PCD via a caspase-3-dependent pathway, which is related 
to increased expression of the proapoptotic protein Bcl-xL but unrelated to 5-LOX activity 
[204]. Moreover, it is known that some LOX products (namely, 12- or 15-S-HETE, but not 
their metabolic precursors 12- or 15-HPETE) may protect cells from apoptosis, whereas 
others (5-HETE) are toxic [197, 198, 217]. Maccarrone et al. reported that, within the 
physiological range, 15-LOX-1  dose-dependently increased the oxidative index of leukaemia 
cells (up to threefold over the control) and the uncoupling of mitochondria, both indicative of 
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the disruption of membrane integrity. Remarkably, incubation of mitochondria with 15-LOX-1 
also caused a dose-dependent release of cytochrome c (up to fivefold over the control), a 
critical trigger of apoptosis induced by several unrelated stimuli [248]. Taken together, LOXs 
are able to disrupt mitochondrial integrity and to trigger cytochrome c release, thus giving a 
biochemical explanation for the observation that activation of these enzymes is critical in 
different models of apoptosis. In this study, an increased rate of apoptosis in pancreatic 
cancer cell lines over-expressing  15-LOX-1 cell was observed by using a Nexin assay. 
Other studies also support the view that 15-LOX-1 is a critical component of induction of 
apoptosis in cancer cells. As an example, Wu et al. reported that 15-LOX-1 mediates 
apoptosis induced by COX-2 inhibitors in gastric cancer [242] and Shureiqi et al. described 
that NSAIDs, the non-selective inhibitors of COX induce apoptosis in esophageal and 
colorectal cancer cells by restoring 15-LOX-1 expression [195, 249]. It has further been 
published that administration of the COX-2-selective inhibitor celecoxib restores 15-LOX-1 
protein expression and induces apoptosis in colorectal cancer [250]. Yu et al. published that 
conditional, highly selective induction of 15-LOX-1 caused an inhibition of ribonucleotide 
reductase activity, cell cycle arrest in G1, impairment of anchorage-independent growth, and 
accumulation of the pro-apoptotic protein BAX [251].  
Possible mechanisms underlying 15-LOX-1 induced growth inhibition in colon cancer were 
identified by Zuo et al. They showed that (a) 15-LOX-1 catalyzed formation of 13-S-HODE 
promoted PPAR-γ activity, (b) PPAR-β/δ expression suppressed PPAR-γ activity in models of 
both loss and gain of PPAR-β/δ function, (c) 15-LOX-1 activated PPAR-γ by down-regulating 
PPAR-β/δ, and (d) 15-LOX-1 expression induced apoptosis in colon cancer cells via 
modulating PPAR-β/δ-mediated suppression of PPAR-γ. These findings elucidate a novel 
mechanism of signaling by natural ligands of PPARs, which involves the modulation of the 
interaction between PPAR-β/δ and PPAR-γ [252]. Based on these findings further 
investigations of 15-LOX-1 mediated growth inhibition in pancreatic cancer can be carried 
out. Preliminary data obtained in this study indicate that 15-LOX-1 expression is linked to 
dephosphorylation of ERK and MEK, leading to inactivation of this MAP kinase pathway 
molecules. It is well known that most human pancreatic cancers harbor mutations in the K-
ras oncogene [253, 254]. Ras has been shown to mediate activation of various downstream 
targets, including the family of the MAPKs. One of the three well-defined MAPK pathways is 
the ERK pathway. ERK is involved in cell proliferation and transformation [255-258]. The 
relation between ERK and apoptosis has already been described by several groups. 
Anderson et al. and Xia et al. showed that ERK1/2 activation promotes the anti-apoptotic 
functions of Bcl-2 and cell survival in neuronal PC12 cells [259, 260]. Berra et al. further 
could show that inhibition of basal ERK1/2 activity was sufficient to trigger apoptosis in HeLa 
cells [261]. Studies for pancreatic cancer cells have been carried out by Boucher et al.[262]. 
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They demonstrated that MEK/ ERK signalling pathway regulates the expression of Bcl-2, Bcl-
xL, and Mcl-1and promotes survival of human pancreatic cancer cells. Similar to this study, 
they used MiaPaCa2, a cell line which is known to exhibit activating mutations in the small 
GTPase K-ras [263]. Bocher et al. showed that inhibition of basal ERK activities causes (1) a 
G1 arrest; (2) a down-regulation of the expression levels of anti-apoptotic homologs; (3) a 
promotion of caspase-3 and caspase-8 activities; (4) a stimulation of PARP cleavage; and (5) 
a programmed cell death by apoptosis. In this study I could show that 15-LOX-1 is related to 
apoptosis, and preliminary data indicated that 15-LOX-1 on the same time inhibits 
phosphorylated MEK/ ERK (data not shown). Taken together I postulate following pathway 
for 15-LOX-1 or 15-S-HETE induced apoptosis. 
15-LO X-1
15-S-HETE
M EK
ERK
pro-apoptotic
Bcl-2 m em bers
?
apoptosis
anti-apoptotic
Bcl-2 m em bers
?
caspases
?
Fig 34: Postulated 15-LOX-1 induced apoptosis pathway 
 
In contrast, Yoshinaga et al. described that over-expression of 15-LOX-1 induced 
extracellular signal-related kinase (ERK) 1/2 phosphorylation, decreased p21 (Cip/WAF 1) 
expression, and increased HCT-116 cell growth. Treatment with NDGA decreased ERK 1/2 
phosphorylation, and increased p21 (Cip/WAF 1) expression in 15-LOX-1 over-expressing 
HCT-116 cells. In these colon carcinoma cells the 15-LOX-1 effects also were shown to be 
mediated via the LA product 13-S-HODE and the results support the hypothesis that          
15-LOX-1  may have "pro-neoplastic" effects during the development of colorectal cancer 
[220]. Opposing effects of 15-S-HETE and 13-S-HODE on MAPK signaling in prostate 
cancer cells was reported by His et al. 13-S-HODE up-regulated MAP kinase and 
subsequentely increased PPARγ phosphorylation which was linked to a decreased PPARγ 
transcriptional activity and subsequently to enhanced proliferation, whereas 15-S-HETE  
down-regulated MAP kinase, decreased PPARγ phosphorylation which was linked to 
increased  differentiation. 
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13.3 Effect of LOX and HDAC inhibitors 
 
In this study, it was shown that LOX inhibitors like NDGA and baicalein did not reverse the 
15-LOX-1 mediated growth inhibition but on the same time did inhibit cell proliferation per se 
to add up to about 100% in pancreatic tumor cell lines. Several groups already published 
same effect for NDGA in lympholeukemia cells [264], breast cancer cells [265], urological 
cancers [266], and several other cancers [267]. Similar results have been published for the 
treatment with baicalein. The 12-LOX-selective inhibitor baicalein significantly inhibited 
proliferation in cultures of the epidermoid carcinoma cells A431 as described by Kudryavtsev 
et al. [268]. Growth inhibition post baicalein treatment has also been described in human 
prostate cancer cells [269] as well as in pancreatic cancer xenografts [270]. In consideration 
of the fact that LOX inhibitors by themselves inhibit proliferation of several tumor cells it is 
conceivable that 15-LOX-1 mediated growth inhibition can not be reversed by these 
inhibitors. 
Not only LOX inhibitors but also histone deacetylase (HDAC) inhibitors have been shown to 
be potent inducers of growth arrest, differentiation, and/or apoptotic cell death in transformed 
cells in vitro and in vivo. Target of the inhibitor action is the catalytic site of HDAC that has a 
tubular structure with a zinc atom at its base. The HDAC inhibitors, such as sodium butyrate 
(NaBu), suberoylanilide hydroxamic acid (SAHA), and Trichostatin A (TA), fit into this 
structure, in the case of SAHA, with the hydroxamic moiety of the inhibitor binding zinc. 
HDAC inhibitors cause acetylated histones to accumulate in both tumor and normal tissues. 
In general, chromatin fractions enriched in actively transcribed genes are also enriched in 
acetylated core histones, whereas silent genes are associated with nucleosomes with a low 
level of actetylation. HDACs also can acetylate proteins other than histones [271]. HDAC 
inhibitors unexceptionally inhibit proliferation of transformed cells in culture, and a subset has 
been shown to inhibit tumor growth in animal models [271]. They perform this activity by 
inducing growth arrest, differentiation, and/or apoptotic cell death in a wide variety of cultured 
transformed cells, including neuroblastoma, melanoma, and leukemia cells, as well as cells 
from breast, prostate, lung, ovary, colon [272-281] and pancreatic cancers [282]. Natoni et al. 
revealed that sodium butyrate sensitizes human pancreatic cancer cells to both the intrinsic 
and the extrinsic apoptotic pathway [282]. Additionally, Farrow et al. showed that pancreatic 
cancer invasion was inhibited by sodium butyrate [283]. Similar to Natoni’s results, growth 
inhibition after NaBu treatment in both tested cell lines was observed in this study. 
Furthermore, inhibition in cell growth was also achieved after treatment with two other HDAC 
inhibitors, namely Trichostatin A and SAHA supporting similar observations that were made 
previously in other models. Desai et al. showed that SAHA markedly inhibited tumor growth 
in a mouse lung cancer model [284]. Kuefer et al. reported growth inhibition and apoptosis in 
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human prostate cancer in vivo after sodium butyrate and tributyrin treatment [285]. Beside 
growth inhibitor properties, HDAC inhibitors have also been published to restore 15-LOX-1 
expression in colon cancer [286, 287]. Taken together, 15-LOX-1 may play a critical role in 
the control of epithelial cell growth and the loss of 15-LOX-1 expression and activity might 
contribute to the progression of cancer. In addition it was shown recently that down-
regulation of 15-LOX-1 is an early event in the adenoma to carcinoma sequence both in 
colonic and gastric cancer development [240, 242]. This holds also true for pancreatic 
carcinogenesis in that 15-LOX-1 expression has already been lost in advanced PanIN 2 and 
-3 lesions that are regarded as precursor lesions for ductal adenocarcinoma as well as in 
cancer cells but not in PanIN-1 lesions. It is widely accepted that PanIN-1 lesions that are 
also found in many non-malignant pancreatic tissues do not yet fulfill the conditions of a 
premalignant lesion. Therefore, the switch to develop pancreatic cancer may happen at 
PanIN-2 stage, concomitant with the loss of 15-LOX-1 expression [238]. Thus, the 
modulation of 15-LOX-1 expression may be an attractive measure for the prevention and 
treatment of early pancreatic cancer. There are several pathways that are involved in the 
regulation of 15-LOX-1 expression. COX-2 inhibitors induce 15-LOX-1 expression, via down-
regulation of the transcription factor GATA-6 [288]. Recently, Shureiqi et al. showed that 
GATA-6 is overexpressed in in vivo and contributes to silencing 15-LOX-1 in vitro in human 
colon cancer. Moreover, GATA-6 knockdown though being insufficient by itself to restore 15-
LOX-1 expression, contributes significantly to the restoration of 15-LOX-1 expression [289]. 
Furthermore, an important role for the cGMP/PkG pathway in the restoration of 15-LOX-1 
activity was suggested [290]. In addition, IL4 & IL13 were shown to stimulate the expression 
of 15-LOX-1, which than can induce p53 expression and phosphorylation/activation [56, 221]. 
Other research groups found the 15-LOX-1 promoter completely methylated in cells that are 
unable to express this enzyme and that 5-aza-2-deoxycytidine (5-Azadc), a potent 
methyltransferase inhibitor (MTI), induces the expression of 15-LOX-1 in human colorectal 
cancer cells [291]. Reversing epigenetic silencing, e.g. with an MTI as 5-Azadc, has become 
a new and important target approach for cancer prevention and therapy [291]. Another 
possibility to induce 15-LOX-1 expression is the use of sodium butyrate, a HDAC inhibitor 
[286]. In agreement with published data I could show in this study that 15-LOX-1 expression 
could be restored after treatment with the HDAC inhibitor NaBu. Whether SAHA has the 
same effect on 15-LOX-1 expression has yet to be confirmed. Besides the restoration of 15-
LOX-1, up-regulation of KAI1, an anti-metastatic protein, could be demonstrated in this study. 
Similar findings have been described by Joseph et al. in prostate cancer cells [292]. It 
remains to be shown if both anti-cancer proteins are co-regulated upon induction of 15-LOX-
1 expression.  
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In future experiments, the anti-tumorigenic function of 15-LOX-1 in human pancreatic cancer 
has to be subject to a detailed mechanistic analysis in order to provide the foundation for the 
development of preventive measures or the intervention in early stages of pancreatic cancer  
To this end, cell culture models with inducible 15-LOX-1 expression will be established. 
Moreover, an orthotopic mouse model will be developed to verify the postulated anti-tumor 
activity of 15-LOX-1. Such an experiment will also shed light on the potential anti-metastatic 
activity of 15-LOX-1 in pancreatic carcinogenesis in vivo. 
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